INTRODUCTION
============

Brain volume regulation is a homeostatic process in which the ionic and osmotic balance is maintained by water movement. It is critical for proper function and health of the nervous system and is tightly controlled by a specific cell type called astrocytes due to their high and exclusive expression of the water channel, aquaporin-4 (AQP4) \[[@B1][@B2]\]. The increase of intracellular or decrease of extracellular ionic- and organic-osmolytes initiates water-influx through AQP4 and swelling, which triggers an efflux of Cl^−^ and osmolytes via volume-regulated anion channel (VRAC~swell~), followed by a water-efflux to restore volume. The latter process is called regulatory volume decrease (RVD) \[[@B3][@B4][@B5]\]. The astrocytic VRAC~swell~ has been initially characterized as an intracellular Ca^2+^-independent and kinase inhibitor-sensitive channel \[[@B6]\]. It has been subsequently shown that several organic osmolytes, notably glutamate and taurine which act as neurotransmitters, are released via the astrocytic VRAC~swell~ \[[@B7][@B8][@B9][@B10]\]. Taurine, the most abundant osmolyte has been shown to regulate the glycinergic neurotransmission in the hypothalamus \[[@B11]\]. Moreover, VRAC~swell~ and the released osmolytes have been implicated in several pathophysiological conditions such as cerebral edema following excessive oxidative stress, ischemia, traumatic brain injury and glioma \[[@B12][@B13][@B14][@B15][@B16]\]. VRAC~swell~ is also associated with many other general functions including regulation of cell cycle, apoptosis, proliferation and cellular mobility \[[@B17][@B18]\]. Reduction of VRAC~swell~ and impairment of apoptotic volume decrease have been linked to a multi-drug resistance (MDR) to chemotherapy in several cancer cells \[[@B19][@B20]\]. Although the pathophysiological functions of the astrocytic VRAC~swell~ and the released osmolytes are becoming increasingly highlighted, the precise molecular and cellular mechanisms of VRAC~swell~ activation and related functions are still poorly understood due to the lack of molecular identity of the astrocytic VRAC~swell~.

Over the years, many Cl^−^ channels and transmembrane proteins have been proposed as the molecular identity of VRAC~swell~ but tested with no success \[[@B17][@B21][@B22][@B23][@B24]\]. Since 2014, LRRC8A has been proposed as a necessary component of VRAC~swell~ in various cell lines by providing evidence of the reduction of I~Cl,swell~ with *Lrrc8a* siRNA \[[@B25][@B26]\]. Unexpectedly, reconstitution of the LRRC8A-containing complex into lipid bilayers was sufficient to form anion channels activated by low intracellular ionic strength (Γ) rather than cell swelling itself \[[@B27]\]. Moreover, an overexpression of LRRC8 isoforms not only failed to induce larger I~Cl,swell~ over the endogenous levels in various cell line such as HEK293T, HeLa cells \[[@B25][@B26]\], but also failed to restore VRAC~swell~ activity in cisplatin-resistant KCP-4 cells \[[@B28]\]. These results indicate that LRRC8A is not sufficient for VRAC~swell~ in HEK293T, HeLa and KCP-4 cells. In a very recent study, the crystal structure of the LRRC8 family consisting of a transmembrane pore domain activated at low cytoplasmic Γ has been determined \[[@B29]\], indicating that LRRC8 family is the VRAC activated by the lower cytosolic Γ (VRAC~Γ~), rather than VRAC~swell~. Therefore, these previous findings strongly suggest that there exists a separate molecular component for VRAC~swell~ in astrocyte.

Consistently, it has been clear that LRRC8-mediated VRAC~Γ~ and the astrocytic VRAC~swell~ do not share the same biophysical and biochemical properties. LRRC8-mediated VRAC~Γ~ in HEK293T and HeLa cells were reported to be Ca^2+^-dependent as evidenced by the sensitivity to both extracellular zero Ca^2+^ and intracellular BAPTA \[[@B30][@B31]\]. Moreover, a G protein-coupled receptor (GPCR)-mediated activation of astrocytic VRAC was also shown to be dependent on the local Ca^2+^ in nanodomains \[[@B32]\]. In contrast, the swelling-activated VRAC, which was firstly reported in human epithelial cells (intestine 407), was demonstrated to be totally independent of Ca^2+^ \[[@B5]\]. More importantly, astrocytic VRAC~swell~ was shown to be Ca^2+^-independent \[[@B6]\]. These results suggested that there exist two-types of VRACs in astrocytes: Ca^2+^-dependent and Ca^2+^-independent components of VRAC. In addition, there has been no evidence that LRRC8-mediated VRAC~Γ~ is sensitive to kinase inhibitors, which happens to be a unique property of the astrocytic VRAC~swell~ \[[@B6]\]. Furthermore, the glutamate permeability ratio, P~glu~/P~Cl~, of LRRC8-mediated VRAC~Γ~ was previously reported as near 0.2 \[[@B33]\]. In contrast, the astrocytic VRAC~swell~ has been directly shown to display a higher glutamate permeability \[[@B8]\]. Interestingly, the glutamate- and GABA-permeable Ca^2+^-activated anion channel BEST1 \[[@B34][@B35]\], but not LRRC8A, was shown to encode Aqp4-dependent VRAC~swell~ in retinal pigment epithelial cells differentiated from human-induced pluripotent stem cells (hiPSC-RPE) \[[@B31][@B36]\], suggesting that anion channels other than LRRC8A could be responsible for the astrocytic VRAC~swell~. More importantly, mechanically-induced ATP release in astrocyte was shown to be mediated possibly by VRAC~swell~ as evidenced by the sensitivity to a known VRAC inhibitor, DCPIB \[[@B37]\]. However, this was not impaired by gene-silencing of LRRC8A, suggesting an involvement of other unidentified component of VRAC~swell~ \[[@B37]\]. Therefore, the molecular identity of the astrocytic VRAC~swell~ still remains unknown.

Previous studies reported that the maxi-chloride channels share the common physiological, biophysical and pharmacological profiles with VRAC~swell~ \[[@B38]\]. Human TTYH1, but not TTYH2 and 3, was initially described as putative maxi-chloride anion channels, activated by hypo-osmotic solution (HOS) \[[@B39]\], which was disproven later \[[@B40]\]. Recently, TTYH1 was confirmed to be a potent regulator of tumor microtubule morphology, invasion, and proliferation of glioma, which are the known functions of VRAC~swell~ \[[@B41]\]. Brain transcriptome analysis by RNA sequencing showed that in astrocytes TTYH1 and 3 were the top 49^th^ and 94^th^ among 22,458 genes ranked by expression level \[[@B42]\]. Furthermore, Ttyh1/2/3 showed 11-, 12-, and 3-fold higher mRNA level in astrocyte compared to neuron in the brain \[[@B42]\]. Therefore, Ttyh1/2/3 should be considered as potential candidates of the astrocytic VRAC~swell~.

In this study, we set out to determine the true molecular identity of the astrocytic VRAC~swell~, activated by AQP4-dependent swelling. Many previous studies of VRAC~Γ~ and VRAC~swell~ have used external and internal solutions that contained cations such as Na^+^, K^+^, and Cs^+^, which might have allowed the investigators to inadvertently record currents contaminated by cations. We have utilized a special recipe of external and internal solutions consisting only Cl^−^ as the permeating ion to eliminate any contribution of cations Na^+^, K^+^ and to minimize Cs^+^ for the recording of genuine I~Cl,swell~, as previously described for the recording of VRAC~swell~ current in cultured astrocyte \[[@B6]\]. We have identified and characterized Ttyh1/2/3, not LRRC8A nor BEST1, as the pore-forming subunits of the astrocytic VRAC~swell~.

MATERIALS AND METHODS
=====================

Animals and housing
-------------------

C57BL/6J mice and hGFAP-CreERT2 were used at 8\~10 weeks of age. The hGFAP-CreERT2 mice are inducible transgenic mice under control of human *GFAP* promoter and estrogen. All mice were kept on a 12 hours light-dark cycle in a specific-pathogen-free facility with controlled temperature and humidity and had free access to food and water. All experimental procedures were conducted according to protocols approved by the directives of the Institutional Animal Care and Use Committee of KIST (Seoul, Republic of Korea).

Primary mouse astrocyte culture
-------------------------------

Primary cultured astrocytes were prepared from cortex of C57BL/6 mouse pups (P0-P2) as described \[[@B37]\]. The cerebral cortex was dissected from the brain and adherent meninges were removed, minced and dissociated into single cell suspension by trituration. Cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM, \#10-013, Corning) supplemented with (in mM) 25 glucose, 4 L-glutamine, 1 sodium pyruvate, 10% heat-inactivated horse serum (\#260500-088, Gibco), 10% heat-inactivated fetal bovine serum (\#10082-147, Gibco) and 10,000 units/ml penicillin-streptomycin (\#15140-122, Gibco). Cultures were maintained at 37℃ in a humidified 5% CO~2~ incubator. On DIV3, cells were vigorously washed with repeated pipetting and the media was replaced to get rid of debris and other floating cell types. During maintaining the culture before use, the media was replaced every 3\~4 days. For gene-silencing experiments with primary cultured astrocytes, various shRNA vectors were electroporated (Neon Transfection system kit; \#MPK10096, Invitrogen) into trypsinized cultured astrocytes 4 days before the experimental day and replated onto culture dish. One day before the experimental day (for recording I~Cl,swell~, DIV21 primary astrocyte culture were used), cells were replated onto cover-glass coated with 0.1 mg/ml Poly D-Lysine (PDL, \#P6407, Sigma-Aldrich).

Cell lines culture
------------------

Human embryonic kidney 293T (HEK293T) and Chinese hamster ovary-K1 (CHO-K1, referred as CHO) cells were purchased from ATCC (\#CRL-3216, ATCC) and the Korean Cell Line Bank (Seoul National University, Republic of Korea), respectively. All cell lines have been tested for mycoplasma contamination. HEK293T cells and CHO cells were cultured in DMEM (\#10-013, Corning) and F-12 (\#21127-022, Gibco), respectively. Both media were supplemented with (in mM) 25 glucose, 4 L-glutamine, 1 sodium pyruvate, 10% heat-inactivated fetal bovine serum (\#10082-147, Gibco) and 10,000 units/ml penicillin-streptomycin (\#15140-122, Gibco). Cell lines were maintained at 37℃ in a humidified atmosphere of 95% air and 5% CO~2~. 18 hours before the experimental day, cells were transfected with DNA clone by transfection reagent (Effectene, \#301425, Qiagen). On experiment day, the transfected cells were replated onto cover-glass for electrophysiological recordings. For immunocytochemistry, HEK293T cells were plated onto PDL coated cover-glass, and transfected with DNA clone 20 hours before fixation.

shRNA vector construction
-------------------------

Various kinds of shRNA were synthesized as for following: Two kinds of oligos were purchased (Sequence of oligos; \[phos\]5′-t \[sense sequence of target\] ttcaagaga \[reverse complement sequence of target\] ttttttc-3′ and \[phos\]5′-tcgagaaaaaa \[sense sequence of target\] tctcttgaa \[reverse complement sequence of target\] a-3′). The sequence information for control shRNA and various candidates of shRNA are listed in [Table 1](#T1){ref-type="table"}.Two oligos were annealed with annealing buffer (in mM; 200 potassium acetate, 60 HEPES-KOH, 4 Mg-acetate, pH 7.3 was adjusted by KOH) and incubated at 95℃ for 5min and 70℃ for 10 min. The annealed double-stranded oligo was inserted into HpaI-XhoI restriction enzyme sites of pSicoR lentiviral vector \[[@B44]\] (\#11579, Addgene) and verified by sequencing. The shRNA containing pSicoR vectors were electroporated into cultured astrocytes. In experiments using triple combination of *TTYH* shRNA, we used either (pSicoR-*Ttyh1*-shRNA-GFP, pSicoR-*Ttyh2*-shRNA-mcherry and pSicoR-*Ttyh3* shRNA-mcherry) or (pSicoR-scrambled-shRNA-GFP and pSicoR-scrambled-shRNA-mcherry). The sequence of each shRNAs are listed in the [Table 1](#T1){ref-type="table"}.

Stereotaxic surgery for virus delivery
--------------------------------------

The 7\~9 weeks old male mice were anesthetized with 2% tribromoethanol (Avertin, 20 µl/g) and placed in a stereotaxic frame. The scalp was incised and exposed the skull. The connective tissue was gently scraped away. Stereotaxic coordinates were: AP: −1.7 mm; L: 1.7 mm; and DVL:−1.85 mm, according to Allen Mouse Brain Atlas ([http://www.brain-map.org](https://www.brain-map.org)). The cocktail of lentiviruses carrying either (pSicoR-*Ttyh1*-shRNA-GFP, pSicoR-*Ttyh2*-shRNA-mcherry, and pSicoR-*Ttyh3*-shRNA-mcherry) or (pSicoR-scrambled-shRNA-GFP and pSicoR-scrambled-shRNA-mcherry) were bilaterally injected into hippocampal CA1 stratum radiatum of naïve C57BL/6J mice for slice patch-clamp recording or tamoxifen-treated hGFAP-creERT2 mice for intrinsic optical signal (IOS) imaging. The adeno-associated virus (AAV) of Lentivirus carrying pSicoR-*Ttyh1*-shRNA-GFP or scrambled-shRNA-GFP was also injected into the CA1 *stratum radiatum* of naïve C57BL/6J mice for confirming the knock-down efficiency with immunohistochemistry. 10\~14 days after virus delivery by stereotaxic injection, the mice were sacrificed for next experiments at 9\~10 weeks of age.

Astrocyte-specific rescue by tamoxifen-driven action of Cre-recombinase
-----------------------------------------------------------------------

The tamoxifen-inducible Cre-mediated recombination is expected to result in deletion of the floxed sequences. To activate Cre recombinase, 7\~9 weeks-old male mice were administrated with tamoxifen (\#T5648, Sigma-Aldrich) once a day (200 mg per kg of body weight, intraperitoneal) for 7 days. Tamoxifen was dissolved in sunflower oil (\#1642347, Sigma-Aldrich) with 10% ethanol at a final concentration of 20 mg per milliliter at room temperature, and stored at 4℃ in the dark. The shRNA is floxed with loxP sites in the pSicoR construct, which is cleaved by Cre-expression \[[@B44]\]. The cocktail of lentiviruses carrying pSicoR-*Ttyh1*-shRNA-GFP, pSicoR-*Ttyh2*-shRNA-mcherry and pSicoR-*Ttyh3*-shRNA-mcherry were injected into CA1 *stratum radiatum* of the hippocampus in tamoxifen-treated hGFAP-creERT2 transgenic mice, which allowed us to achieve astrocyte-specific recovery of TTYH family expression in the hippocampal CA1 *stratum radiatum*.

Construction of Ttyh1-shRNA-insensitive-GFP vector
--------------------------------------------------

The design for *Ttyh1*-shRNA-insensitive-GFP clone construction was done by changing every third single nucleotide of *Ttyh1* shRNA target site to another nucleotide that makes same amino acid due to the codon redundancy (*Ttyh1*-shRNA target sequence- 5′- GCACAGAAGCCCTTGTTATCC -3′; shRNA-insensitive sequence- 5′-GCGCAAAAACCTTTATTGTCA-3′ included 7 mismatches, also described in [Fig. 2B](#F2){ref-type="fig"}). The site-directed mutagenesis kit was used for the construction of *Ttyh1*-shRNA-insensitive-GFP vector (Ezchange™ site-directed mutagenesis kit, EZ400, Enzynomics). The sequence information of oligomers for cloning of mutants clone are listed in [Supplemental Table 2](#S2){ref-type="supplementary-material"}.

Construction of truncation and single amino acid mutant vector
--------------------------------------------------------------

All truncation mutant and single amino acid mutants of TTYH1 were constructed in shRNA-insensitive TTYH1 tagged with GFAP clone (*Ttyh1* shRNA-insensitive-EGFP). Also, a single amino acid mutant of TTYH2 or TTYH3 were constructed in TTYH2 or TTYH3-IRES2-EGFP clone. All truncations, single amino acid mutants, and shRNA insensitive clones were made by site-directed mutagenesis kit (Ezchange™ site-directed mutagenesis kit, EZ400, Enzynomics).

Drugs and chemicals
-------------------

4-(2-butyl-6,7-dichloro-2-cyclopentylindan-1-on-5-yl)oxybutyric acid (DCPIB), 2-(2-Amino-3-methoxyphenyl)-4*H*-1-benzopyran-4-one (PD98059) were purchased from Tocris (\#1540, 1213). 4′,5,7-Trihydroxyisoflavone, 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one (Genistein) was purchased from Sigma-Aldrich (\#G6649). Other chemicals used for recording solution of electrophysiology and intrinsic optical signal imaging were purchased from Sigma-Aldrich.

Electrophysiology and solutions
-------------------------------

For VRAC current (herein defined as Cl^−^ current induced by hypo-osmotic stimulation, I~Cl,swell~) recording, primary cultured cortical astrocyte or transfected HEK292T or CHO cells, and acute hippocampal slices from 8\~10 weeks mice were used for *in vitro* and *ex vivo* (slice) whole cell patch clamp recording, respectively. The preparation procedures with cultured coverslip and hippocampal slices followed a previous report \[[@B43]\]. In both *in vitro* and *ex vivo* whole cell patch clamp recording, we use the same internal and external solution; isotonic (ISO), hypo-osmotic solution (HOS). In case of *ex vivo* whole-cell patch clamp recording, the slices were left to recover for at least 1 hour before recording in oxygenated (95% O~2~ and 5% CO~2~) artificial cerebrospinal fluid (aCSF) containing (in mM) 130 NaCl, 24 NaHCO~3~, 3.5 KCl, 1.25 NaH~2~PO~4~, 1 CaCl~2~, 3 MgCl~2~ and 10 glucose (pH 7.4) at room temperature. After 1 hour, the slices were placed on a chamber with an aCSF solution. After complete rupture of the cell membrane, the external aCSF was changed to standard ISO solution for baseline recording.

Standard external bath solutions of both ISO and HOS for VRAC~swell~ were composed of (in mM): 70 Tris-HCl, 1.5 CaCl~2~, 10 HEPES, and 10 glucose, 5 TEA-Cl, 5 BaCl~2~ and adjusted to pH 7.3 with CsOH, as previously described \[[@B6]\]. The osmolality of each solution was adjusted with sucrose: 100 mM sucrose for 280\~290 mOsm (for ISO) and 30 mM sucrose for 220\~230 mOsm (for HOS), Solution osmolality was confirmed by a vapor pressure osmometer (Vapro osmometer \#5600, Wescor). The external solution of both ISO(NaCl) and HOS(NaCl) for recording of LRRC8-mediated VRAC~Γ~ was composed of (in mM) : 150 NaCl for ISO(NaCl), 105 NaCl for HOS(NaCl), respectively, 6 KCl, 1 MgCl~2~, 1.5 CaCl~2~, 10 Glucose, 10 HEPES, adjusted to pH 7.4 with NaOH. The solution osmolality is 320mOm for ISO(NaCl) and 240mOsm for HOS(NaCl). For Ca^2+^ dependency with TTYH mediated I~Cl,swell~, 1.5 mM CaCl~2~ is changed to 0.15 mM CaCl~2~ for all external bath solution. TEA-Cl and BaCl~2~ were added to eliminate the potassium currents enabling selective recording of Cl^−^ current. For glutamate permeability experiments, 70 mM Tris-Cl containing HOS external solution was substituted for 70 mM Tris-base and 70 mM glutamate (glutamate containing HOS, gHOS) to omit external Cl^−^. When the maximal current was generated after standard HOS treatment, the standard HOS (70 mM Tris-Cl) was changed to gHOS (70 mM Tris-glutamate). The reversal potentials from both standard HOS (70mM Tris-Cl) and gHOS (70mM Tris-glutamate) were measured to calculate the ratio of glutamate permeability (detailed description in the analysis of electrophysiological data).

For the recording of various anion (SCN^−^, I^−^, Br^−^, and F^−^) permeability, 105mM of NaCl in HOS (NaCl) was changed to the same concentration, 105mM of NaSCN, NaI, NaBr, and NaF at the maximal conductance of VRAC~swell~ or VRAC~Γ~ recording. The reversal potentials from each HOS(NaCl) (105mM NaCl) and HOS(NaX^−^) (105mM NaSCN, NaI, NaBr, and NaF) were measured to calculate ratio of ion permeability (The calculating equation for of relative anion permeability is the same with glutamate permeability, detailed description in analysis of electrophysiological data).

Standard internal solution for VRAC~swell~ was composed of (in mM) : 60 Trizma-HCl, 70 Trizma-base, 70 Aspartic acid, 15 HEPES, 0.4 CaCl~2~, 1 MgCl~2~, 4 Mg-ATP, 0.5 Na-GTP, and 1 EGTA, adjusted to pH 7.25 with CsOH, as previously described \[[@B6]\].

The internal solution for recording of LRRC8-mediated VRAC~Γ~ was composed of (in mM) : 40 CsCl, 100 CsMeS, 1 MgCl~2~, 1.9 CaCl~2~, 5 EGTA, 4 Na2ATP, 10 HEPES, adjusted to pH 7.2 with CsOH, as previously described(Voss et al., 2014). For Ca^2+^ free experiment, 1mM EGTA was replaced into 20mM BAPTA which leads 100nM free Ca^2+^ to be reduced by 10nM. Patch pipettes had tip resistances of 5\~8MΩ when filled with internal solution. Pipettes were pulled from borosilicate thin-wall glass capillaries (TW150F-4, World Precision Instruments) with the micropipette puller (P-97, Sutter Instrument). Unlike other previous studies \[[@B25][@B26]\], we used Tris·Cl-based external solution without Na^+^ and K^+^ and minimal level of Cs^+^ (15mM of CsOH for pH adjustment of external solution), and Tris·Cl-based internal solution to eliminate any contribution of Na^+^, K^+^ and to minimize Cs^+^ to I~Cl,swell~. This is particularly important for isolating the anionic current (See [Table 2](#T2){ref-type="table"}).

For substituted-cysteine accessibility method (SCAM), 10 amino acids in TTYH1 (from V161 to A170) were each substituted with cysteine residue. The cysteine mutant of TTYH1 or TTYH1-WT were co-transfected with AQP4 in HEK29T cells. The standard bath solution of HOS containing MTSES (100mM) was applied at the maximal I~Cl,swell~. The percent block was determined.

To test the dominant negative function of TTYH1-R165A, pEGFP-N1-TTYH1-WT and pEGFP-N1-TTYH1-R165A were co-expressed with mAQP4-M1-mcherry in HEK293Tcells. The total DNA amount of TTYH1 (WT or R165A) is 2 mg and AQP4 is 750ng. The relative amount of R165A to WT is varied with 1:0, 0.75:0.25, 0.5:0.5, 0.25:0.75, and 0:1. The maximal current of I~Cl,swell~ was recorded in each condition by treatment of a standard solution of HOS.

To identify shRNA-transfected or infected astrocytes from primary cultures or hippocampal slices, GFP or mcherry fluorescence was used ([Fig. 10D](#F10){ref-type="fig"} and [11J](#F11){ref-type="fig"}), which were driven under CMV promoter in pSicoR vector construct ([Fig. 11I](#F11){ref-type="fig"}). In the case of hippocampal slices, astrocytes were distinguished by electrophysiological properties such as low membrane resistance (Rm), low resting membrane potential after rupturing. The whole cell configuration was achieved by rupturing the cell membrane with suction after achieving a giga-seal. Holding voltage was −60 mV. Stability and quality of the patch were determined by monitoring the cell parameters: Rm, cell capacitance (Cm), and series resistance (Ra).

The episodic ramp protocol (+100 mV to −100 mV, 1000 ms, 15 s interval) for measurement of the maximal conductance of VRAC~swell~ and VRAC~Γ~ and the current step protocol (from−100 mV to +140 mV with 20 mV step) for measurement of the voltage-dependent inactivation of VRAC~swell~ and VRAC~Γ~ were given and recorded with a Digidata 1322A interface and pClamp10 software (Molecular Devices). A continuous gap-free recording was simultaneously conducted with Minidigi digitizer and Axoscope10 software (Axon Instruments).

Analysis of electrophysiological data
-------------------------------------

For drawing the I\~V curve for I~Cl,swell~, the averaged mean value and standard error of mean (SEM) at every 5 mV are plotted. The current density (pA/pF) of I~Cl,swell~ was measured by subtraction of maximal Cl^−^ current (average of maximal 4weeps in HOS treatment) from basal Cl^−^ current (average 4weeps of ISO treatment, 1 min before HOS treatment) divided by the capacitance of the membrane (Cm), and measured the amplitude of current density (pA/pF, from −100 mV to 100 mV) by I~Cl,swell\ (at\ 100\ mV)~ -- I~Cl,swell\ (at\ −100\ mV)~. Rectification index was defined here as the following equation.

$$Rectification\quad index = \left| \frac{\left. I_{{cl}^{-},\quad swell} \right|_{- 100mV}}{\left. I_{{cl}^{-},\quad swell} \right|_{+ 100mV}} \right|$$

To examine the glutamate permeability (P~Glu~) of VRACs, we measured the reversal potential shift of I~Cl,swell~ caused by external solution change from standard HOS solution (70 mM Tris-Cl) to gHOS (70 mM Tris-glutamate) solution, which was corrected for junction potential (9.4mV). The detailed composition of the gHOS solution is described above. The reversal potential of I~Cl,swell~ was calculated with following Goldman-Hodgkin-Katz (GHK) equation.

$$E_{rev} = \frac{RT}{F}*ln\left( \frac{P_{cl}\left\lbrack {Cl}^{-} \right\rbrack_{i} + P_{glu}\left\lbrack {glu} \right\rbrack_{i}}{P_{cl}\left\lbrack {Cl}^{-} \right\rbrack_{o} + P_{glu}\left\lbrack {glu} \right\rbrack_{o}} \right)$$

With this equation, reversal potential difference (Δ*E~rev~*) was calculated as (previously also shown in \[[@B35][@B45]\]).

$${\Delta E}_{rev} = \frac{RT}{F}*ln\left( \frac{P_{cl}\left\lbrack {Cl}^{-} \right\rbrack_{i} + P_{glu}\left\lbrack {glu} \right\rbrack_{i}}{P_{cl}\left\lbrack {Cl}^{-} \right\rbrack_{HOS} + P_{glu}\left\lbrack {glu} \right\rbrack_{HOS}} \right)$$

$$- \frac{RT}{F}*ln\left( \frac{P_{cl}\left\lbrack {Cl}^{-} \right\rbrack_{i} + P_{glu}\left\lbrack {glu} \right\rbrack_{i}}{P_{cl}\left\lbrack {Cl}^{-} \right\rbrack_{gHOS} + P_{glu}\left\lbrack {glu} \right\rbrack_{gHOS}} \right)$$

The 'i' and 'o' indicates internal and external solution respectively. HOS and gHOS represent standard hypo-osmotic stimulation condition and glutamate containing HOS condition respectively.

Intrinsic optical signal imaging
--------------------------------

For IOS imaging devices, Infrared (IR) light source with optical filter (775 nm wavelength, Omega Filters) was used for transillumination of brain slices and these optical signals were obtained as IOS images using a microscope (BX50WI, Olympus) equipped with a CCD camera (ORCA-R2, Hamamatsu). Imaging Workbench software (INDEC Biosystems) was used for image acquisition and image analysis.

For the detailed procedure of experiments, we first prepared mouse brain hippocampal slices (described in the methods for electrophysiology). Next, we fixed hippocampal slice into the recording chamber and positioned electrical stimulator in the CA1 stratum radiatum region. We determined the region of interest (ROI) by calculating 1.5\~2% increase in IOS by single pulse electrical stimulation (20Hz, 1 sec, 200\~300mA). Images were acquired every 1 second and after stabilization of the IOS signal, we acquired 10 min baseline IOS transmittance (T~base~). Next, we applied 1Hz-30min electrical stimulation (which has been previously shown to induce activity-dependent cell swelling \[[@B2]\]) and acquired two IOS indexes required for analysis: maximum IOS transmittance (T~max~) and final IOS transmittance (T~end~). With these defined indicators, we calculated the induced maximal volume increase (b) and regulated volume decrease (a) as T~max~−T~base~ and T~max~−T~end~ respectively ([Fig. 11C, E, and J](#F11){ref-type="fig"}). Finally, the percentage of regulated volume decrease (RVD%) was calculated by

$$RVD\% = \frac{a}{b}*100$$

Quantitative real-time PCR and reverse transcription PCR
--------------------------------------------------------

Gene silencing test with shRNAs that target VRAC candidates including *Best1*, *Ttyh1,2* and *3, LRRC8A* and *C* were tested by quantitative real-time PCR (qRT-PCR). All shRNAs were electroporated into cultured cortical astrocytes. Approximately 3 days after electroporation, total RNA was extracted by using RNA isolation kit (RNeasy Mini Kit, \#74104, Qiagen). cDNA was synthesized by using reverse transcriptase (SuperScript III reverse transcriptase, \#18080-044, Invitrogen). For qRT-PCR, SYBR-green (SYBR Green PCR master mix, \#4309155, Applied Biosystems) were used. Primers for qRT-PCR for each gene were listed in [Supplemental Table 2](#S2){ref-type="supplementary-material"}.

Western blot and surface biotinylation assay
--------------------------------------------

The knock-down efficiency of *mLrrc8a* shRNA or *m/h Lrrc8a* shRNA was confirmed by performing western blot. mLRRC8A-GFP with control or *mLrrc8a* shRNA or *m/h Lrrc8a* shRNA-mcherry were co-transfected with HEK293T cells. After the 30hr, the transfected HEK293T cells were lysed with RIPA buffer (\#R4100, GenDEPOT) containing protease inhibitor cocktail (\#P3100, GenDEPOT). 30 µg of protein lysates were separated by protein electrophoresis using protein gels (\#4561084, BIORAD) and blotted onto PVDF membranes (\#1704156, BIORAD). The blots were incubated overnight at 4℃ with chicken anti-GFP (1:5000, \#AB13970, Abcam) and rabbit anti-b-actin (1:5000, \#AB133626, Abcam). Blots were then washed and incubated with horseradish peroxidase-conjugated rabbit anti-chicken IgY (1:3000, \#AP162P, Millipore), goat anti-rabbit IgG (1:3000, \#AB6721, Abcam), respectively. The immunoreactivity with enhanced chemiluminescence (GE Healthcare Life Sciences). The band intensity was acquired by ImageQuant LAS 4000 (GE Healthcare) and quantified using ImageJ software (NIH). For surface biotinylation, wild-type, several truncated mutant or single amino acid mutants of mTTYH1-EGFP with AQP4 overexpressing HEK293T cells were incubated at 4℃ and washed three times with PBS. Surface-expressed proteins were then biotinylated in PBS containing Ez-link sulfo-NHS-LC-Biotin (Thermo 21335) for 30 min. After biotinylation, cells were washed with quenching buffer (100 mM glycine in PBS) to remove excess biotin and then washed three times with PBS. The cells were then lysed and incubated with high capacity NeutrAvidin-Agarose Resin (Thermo 29204). After three washes with lysis buffer, bound proteins were eluted by SDS sample buffer and subjected to western blot analysis. Primary antibody was rabbit anti-GFP (Millipore, AB3080). The secondary antibody was Donkey anti-rabbit HRP (Amersham, NA9340).

Immunocytochemistry
-------------------

To determine whether the direction of N-, C-terminus, and Loop1 of TTYH1 are located in the cytosolic or extracellular side, HEK293T cells were transfected with TTYH1-EGFP or TTYH1-GFP (Loop1-FLAG), grown on coverslips for 24 hours. The cells were fixed in 4% paraformaldehyde for 30 min at room temperature. The permeabilized group are treated PBS with 3% Triton X-100 for 5 min and the non-permeabilized group is treated PBS for 5min. Non-specific binding was prevented with 1-hour incubation in 2% donkey serums. Cells were incubated the rabbit anti-Ttyh1 (for N-terminus of TTYH1, \#NBP1-59909, Novus Biologicals), anti-GFP (for C-terminus of TTYH1, \#ab13970, Abcam), and anti-FLAG (for Loop1 of TTTYH1, \#F1804, Sigma-Aldrich) primary antibodies for overnight at 4℃. After washing, DyLight 594-conjugated secondary antibody (Jackson lab, 1:400) was added and incubated for 2 hours at room temperature. The cells were washed and mounted, and then observed under a Nikon A1 confocal microscope.

Immunohistochemistry
--------------------

Mice under anesthesia with 2% tribromoethanol (avertine, 20 µl/g) and were trans-cardially perfused with 0.9% saline followed by 4% PFA, and then the brains were removed. The dissected brains were post-fixed with 4% PFA at 4℃ for 18\~24 hours and dehydrated with 30% sucrose at 4℃ for 48 hours. For immunostaining, brain sections with a thickness of 30 µm were cut using a cryostat, blocked with the serum (donkey serum 2%, goat serum 2%, the solution including 0.3% Triton X-100) of the appropriate species for 1 hour and then treated with primary antibodies, including rabbit anti-TTYH1 (1:200, \#NBP1-59909, Novus Biologicals), chicken anti-GFAP (1:500, \#ab5541, Millipore), mouse anit-NeuN (1:500, \#MAB377, Millipore), DAPI (1:5000, \#46190, Chemicon). During over-night. The next day, tissues were rinsed 3 times with 0.1M PBS and subsequently incubated with secondary antibodies conjugated with Alexa Fluor 488, 594 and 647 for 1 hour 30 min. After treating with secondary antibodies, the tissues were washed out with PBS including DAPI staining in the second washing step. After three rinses in PBS, the sections were mounted on slide glasses. Images were acquired on a Nikon A1 confocal microscope.

Analysis of immunohistochemistry
--------------------------------

Statistical analyses were performed using ImageJ software (NIH Image). For analyzing the knock-down efficiency of AAV-virus containing control or *Ttyh1/2/3* shRNA, we measured the TTYH1 intensity in the binary image of GFAP positive (+) cells. The statistical analysis of TTYH1 intensity in GFAP (+) cells between control and *Ttyh1/2/3* shRNA groups were analyzed with the two-tailed Mann-Whitney t-test.

Bioinformatics and statistical analysis
---------------------------------------

Publically available brain RNA-seq data sets \[[@B42]\] of VRAC candidates such as TTYH, LRRC8, BEST family were used in [Fig. 1D](#F1){ref-type="fig"} (<https://web.stanford.edu/group/barres_lab/brain_rnaseq.html>). Multiple alignments of amino acids were processed from CLUSTAL OMEGA (<http://www.ebi.ac.uk/Tools/msa/clustalo/>). The dendrogram was drawn by the PHYLIP program. The prediction of the transmembrane domain of TTYH family was processed by TMHMM (<http://www.cbs.dtu.dk/services/TMHMM/>). The potential phosphorylation site and kinases were predicted by GPS 3.0 (<http://gps.biocuckoo.org/online.php>). Statistical analysis was performed using GraphPad Prism 7.01 software. p\<0.05 was considered statistically significant. No statistical methods were used to predetermine sample size. All statistical analysis results and methods were described in the [Supplemental Table 1](#S1){ref-type="supplementary-material"} for main figures.

Quantification and statistical analysis
---------------------------------------

Statistical parameters including the exact value of n, the definition of center, dispersion and precision measures (mean ± SEM) and statistical significance are reported in the [Supplemental Table 1](#S1){ref-type="supplementary-material"}. All data points are tested if the values come from a Gaussian distribution by D\'Agostino-Pearson omnibus normality test, and then appropriate statistical methods are applied. In figures, asterisks denote statistical significance as ^\*^, p\<0.05; ^\*\*^, p\<0.01; ^\*\*\*^, p\<0.001; ^\*\*\*\*^, p\<0.000, as well as non-significance with NS, p\>0.05. Statistical analysis was performed in GraphPad PRISM 7.

RESULTS
=======

Neither Lrrc8a nor Best1 encodes the astrocytic VRAC~swell~
-----------------------------------------------------------

Previous studies suggested that water movement via AQP4 is critical for an initial volume increase which then somehow triggers an opening of VRAC~swell~ in astrocytes \[[@B46]\]. To test the requirement of AQP4 for activation of VRAC~swell~, we recorded I~Cl,swell~ under voltage-clamp configuration from cultured mouse astrocytes expressing either control or *Aqp4* shRNA. To isolate genuine I~Cl,swell~ without any current contaminated by cations, we used a special recipe of intracellular and extracellular solutions as previously described (see [Table 2](#T2){ref-type="table"} in Materials and Methods) \[[@B6]\]. HOS-treatment caused a slow onset of Cl^−^ conductance increase as a series of vertical lines representing the current trace in response to a periodic voltage ramp from +100 mV to −100 mV ([Fig. 1A](#F1){ref-type="fig"} inset). We found that the I~Cl,swell~ was mostly abolished by *Aqp4* shRNA ([Fig. 1A\~C](#F1){ref-type="fig"}, see [Table 1](#T1){ref-type="table"} in Materials and Methods). Consistent with previous reports \[[@B46]\], these results indicate that astrocytes regulate their volume with water movement through AQP4.

Previously, two groups concurrently reported that LRRC8A is an essential component of VRAC~Γ~ in various cell lines \[[@B25][@B26][@B27]\]. Thus, we tested whether LRRC8A is the major component of VRAC~swell~ in astrocytes. We developed a specific shRNA for *Lrrc8a* and *Lrrc8c*, which shows relatively higher mRNA expression than other Lrrc8 isoforms in cultured astrocytes ([Fig. 1D\~F](#F1){ref-type="fig"}, see [Table 1](#T1){ref-type="table"} in Materials and Methods). We observed that the maximal amplitude of I~Cl,swell~ was not affected by *Lrrc8a* shRNA or *Lrrc8c* shRNA or both ([Fig. 1G\~I](#F1){ref-type="fig"}). Taken together, these results indicate that LRRC8A and C do not contribute majorly to the astrocytic VRAC~swell~.

It has been subsequently contended that BEST1, not LRRC8A, is indispensable for volume regulation in hiPSC-RPE cells \[[@B36]\]. Over the years, we have extensively characterized BEST1 as a Ca^2+^-activated anion channel, localized at peri-synaptic sites of the hippocampal astrocytes, functioning as the glutamate- and GABA-permeable channel in cerebellum and hippocampus, respectively \[[@B47]\]. To test whether there is any contribution of BEST1 in the astrocytic VRAC~swell~, we utilized previously characterized BEST1 knockout mouse \[[@B48]\] and *Best1* shRNA \[[@B45]\]. We observed that I~Cl,swell~ was normally generated in either cultured astrocytes from BEST1 knockout mice or in *Best1* shRNA expressing astrocytes ([Fig. 1J\~O](#F1){ref-type="fig"}), eliminating the possibility that BEST1 contributes to the astrocytic VRAC~swell~. Taken together, the astrocytic VRAC~swell~ is not encoded by *Lrrc8a* or *Best1*.

Ttyh family of genes encode the essential components of the astrocytic VRAC~swell~
----------------------------------------------------------------------------------

We next focused on *Ttyh* family as the candidate genes for VRAC~swell~. Firstly, we confirmed that cultured astrocytes show much higher mRNA expression of *Ttyh1/2/3*, compared to other VRAC~swell~ candidates such as *Lrrc8* and *Bestrophin* family ([Fig. 1D](#F1){ref-type="fig"}), as previously reported \[[@B42]\]. Thus, we developed and tested the *Ttyh* isoform-specific shRNAs ([Fig. 2A](#F2){ref-type="fig"}) on the astrocytic I~Cl,swell~. We found that the astrocytic I~Cl,swell~ was almost completely abolished by a combination of all three *Ttyh1/2/3* shRNAs, but not by a single *Ttyh* shRNA or any combination of double *Ttyh* shRNAs ([Fig. 2E\~H](#F2){ref-type="fig"}). To exclude any possibility of off-target effect by shRNAs, we developed a fully functional shRNA-insensitive clone of TTYH1 ([Fig. 2B\~D](#F2){ref-type="fig"}). We found that in astrocytes co-expressing all *Ttyh1/2/3* shRNAs with shRNA-insensitive form of TTYH1, the I~Cl,swell~ was fully recovered to the control level ([Fig. 2G and 2H](#F2){ref-type="fig"}). Taken together, these results indicate that TTYH family are necessary for the astrocytic VRAC~swell~ with functional redundancy.

The reduction of I~Cl,swell~ by *Ttyh1/2/3* shRNAs might be due to two possibilities: a reduction of the pore-forming subunits of VRAC~swell~ to reduce the amplitude of I~Cl,swell~ or a reduction of a modulatory protein of VRAC~swell~ to reduce the activation kinetics of I~Cl,swell~. To distinguish these two possibilities, we analyzed the current kinetics of I~Cl,swell~ by plotting the average current density of I~Cl,swell~ versus time after HOS treatment ([Fig. 2I and 2K](#F2){ref-type="fig"}). To compare each shRNA condition, we normalized current density by the maximum to calculate the time to reach 50% of peak ([Fig. 2J and 2L](#F2){ref-type="fig"}). We found that the maximal current density at both +100mV and −100mV was dramatically decreased in *Ttyh1/2/3* shRNAs expressing astrocytes compared to control shRNA ([Fig. 2I](#F2){ref-type="fig"}). However, the time to reach 50% of peak was not significantly different ([Fig. 2J](#F2){ref-type="fig"}, inset), suggesting that the current reduction by *Ttyh1/2/3* shRNAs was due to a reduction of the pore-forming VRAC~swell~ subunits. In contrast, we found that the maximal current density at both +100mV and −100mV was not significantly different in *Lrrc8a* shRNA condition compared to control shRNA ([Fig. 2K](#F2){ref-type="fig"}). However, the time to reach 50% of peak in *Lrrc8a* shRNA expressing astrocytes was significantly slower compared to control shRNA condition ([Fig. 2L](#F2){ref-type="fig"}, inset), indicating that *Lrrc8a* shRNA slows the activation of VRAC~swell~ without affecting the maximal amplitude of I~Cl,swell~. Taken together, these results suggest that Ttyh1/2/3 are the essential component of VRAC~swell~, whereas LRRC8A might act as a modulatory channel of VRAC~swell~.

Each TTYH1/2/3 isoform is sufficient for VRAC~swell~ activity
-------------------------------------------------------------

To test if each TTYH isoform confers VRAC~swell~ activity, we transiently expressed each TTYH isoform clone in HEK293T cells together with AQP4 to maximize HOS-induced volume increase and recorded I~Cl,swell~ ([Fig. 3A\~C](#F3){ref-type="fig"}). We found that each TTYH isoform co-expressed with AQP4 showed significantly increased I~Cl,swell~ compared to the condition of AQP4 alone ([Fig. 3A\~C](#F3){ref-type="fig"}), indicating that all three isoforms of TTYH are sufficient for activation of the I~Cl,swell~ in the presence of AQP4 and that each isoform of TTYH family can mediate VRAC~swell~ possibly as a homomeric channel. In marked contrast, LRRC8A has been repeatedly shown to be insufficient for VRAC~swell~ activity in heterologous expression systems \[[@B25][@B26][@B28][@B31]\]. Consistently, we did not observe I~Cl,swell~ in CHO-K1 cells co-expressing LRRC8A and AQP4 ([Fig. 3D\~F](#F3){ref-type="fig"}), indicating that LRRC8A is not sufficient for VRAC~swell~.

The unexpected lack of HOS-induced I~Cl,swell~ in naïve HEK293T cells ([Fig. 3A\~C](#F3){ref-type="fig"}) was a surprising observation which called for further investigation. In the past, LRRC8A-mediated VRAC~Γ~ in naïve HEK293T cells has been recorded with external solution containing cations such as Na^+^, Cs^+^, or K^+^ (see [Table 2](#T2){ref-type="table"} in Materials and Methods). In contrast, the external solutions that we have utilized contain minimal cations as previously described for the recording of astrocytic VRAC \[[@B6]\]. Therefore, we directly tested the two different solutions in native HEK293T cells. By surprise, we found that I~Cl,swell~ was not observed when the native HEK293T cells with endogenous LRRC8A-mediated VRAC~Γ~ was treated with the HOS which contained minimal cations, whereas a robust I~Cl,swell~ was induced by the Na^+^-containing HOS ([Fig. 3G\~I](#F3){ref-type="fig"}), suggesting that an activation of LRRC8A either requires external cation or possesses a sensitivity to Tris. To further confirm whether this I~Cl,swell~ induced by Na^+^-containing HOS was mediated by LRRC8A, we engineered previously reported *Lrrc8a* shRNA \[[@B49]\] which targets both human and mouse LRRC8A ([Fig. 1F](#F1){ref-type="fig"}). We found that the I~Cl,swell~ induced by Na^+^-containing HOS was almost completely eliminated by the *m/h Lrrc8a* shRNA and overexpression of TTYH1 and AQP4 along with *Lrrc8a* shRNA caused a robust I~Cl,swell~ ([Fig. 3J\~L](#F3){ref-type="fig"}), indicating that TTYH1 is sufficient for VRAC~swell~ even in the absence of LRRC8A. Furthermore, the same *m/h Lrrc8a* shRNA did not have any effect on the maximal amplitude of I~Cl,swell~ induced by the HOS which contained minimal cations in astrocytes ([Fig. 3M\~O](#F3){ref-type="fig"}) as well as in TTYH1 and AQP4 over-expressing HEK293T cells ([Fig. 3P\~R](#F3){ref-type="fig"}). These results indicate that LRRC8A-mediated VRAC~Γ~ is profoundly different from TTYH-mediated VRAC~swell~ in its external-cation-dependence and that the astrocytic VRAC~swell~ is distinct from LRRC8A. This conclusion was further strengthened by the observations that TTYH-mediated VRAC~swell~ and LRRC8A-mediated VRAC~Γ~ showed profoundly different voltage-dependent inactivation ([Fig. 4A and 4B](#F4){ref-type="fig"}) and relative permeability to various anions ([Fig. 4D](#F4){ref-type="fig"}), although there was no difference in rectification index ([Fig. 4C](#F4){ref-type="fig"}).

TTYH1/2/3 share the same biophysical, biochemical and pharmacological properties as astrocytic VRAC~swell~
----------------------------------------------------------------------------------------------------------

The astrocytic I~Cl,swell~ was reported to display an outwardly rectifying conductance \[[@B6]\] with a calculated rectification index to be less than one. The rectification index of each Ttyh1/2/3-mediated I~Cl,swell~ was also identical to that of I~Cl,swell~ recorded from cultured astrocytes with a strong outward rectification ([Fig. 4E](#F4){ref-type="fig"}). Crepel et al. also showed that the Ca^2+^ is not essential for the activation of astrocytic VRAC~swell~ \[[@B6]\]. We observed that each of the Ttyh1/2/3-mediated I~Cl,swell~ is also independent of Ca^2+^ as evidenced by the similar amplitude of I~Cl,swell~ in low external Ca^2+^ (0.15mM) and high internal Ca^2+^-chelator BAPTA (20mM) ([Fig. 4F\~H](#F4){ref-type="fig"}). We next examined the pharmacological profiles of astrocytic VRAC~swell~ compared to Ttyh1/2/3-mediated I~Cl,swell~ in HEK293T cells. DCPIB is a known inhibitor for both VRAC~swell~ and VRAC~Γ~ recorded from various cell lines including cultured astrocytes \[[@B50][@B51]\]. We found that DCPIB rapidly blocked I~Cl,swell~ in cultured astrocytes ([Fig. 4I\~K](#F4){ref-type="fig"}) and Ttyh1/2/3-mediated I~Cl,swell~ in HEK293T cells ([Fig. 4L and 4M](#F4){ref-type="fig"}). Taken together, these results indicate that Ttyh1/2/3 share the same biophysical (outward rectification), biochemical (Ca^2+^-independency) and pharmacological (sensitivity to DCPIB) properties as the astrocytic VRAC~swell~.

TTYH1/2/3 share the same kinase-dependency and glutamate-permeability as astrocytic VRAC~swell~
-----------------------------------------------------------------------------------------------

As previously reported, tyrosine kinase (TK) and mitogen-activated protein kinase (MAPK) are essential for activation of the astrocytic VRAC~swell~ \[[@B6]\]. We also confirmed that pre-treatment of TK inhibitor genistein ([Fig. 5A\~C](#F5){ref-type="fig"}) and MAPK inhibitor PD98059 ([Fig. 5E\~G](#F5){ref-type="fig"}) completely abolished I~Cl,swell~ in cultured astrocytes. Each of the Ttyh1/2/3-mediated I~Cl,swell~ was similarly blocked by pre-treated genistein ([Fig. 5A and 5D](#F5){ref-type="fig"}) or PD98059 ([Fig. 5H\~J](#F5){ref-type="fig"}). In fact, the surface expression of TTYH1 was enhanced by HOS treatment, which was prevented by either TK or MAPK inhibitor ([Fig. 5K](#F5){ref-type="fig"}). These results indicate that each TTYH isoform shares the identical kinase-dependency as the astrocytic VRAC~swell~. In contrast, LRRC8A-mediated VRAC~Γ~ showed a profoundly different sensitivity to MAPK inhibitor ([Fig. 5L\~N](#F5){ref-type="fig"}).

Another unique property of the astrocytic VRAC~swell~ is its relatively high P~Glu~/P~Cl~ \[[@B8][@B32][@B52]\]. To measure the P~Glu~/P~Cl~ of I~Cl,swell~, we exchanged the external solution from HOS (83 mM Cl^−^) to glutamate-containing HOS (gHOS: 70 mM glutamate and 13 mM Cl^−^) after reaching a maximal current amplitude of I~Cl,swell~ ([Fig. 5O](#F5){ref-type="fig"}). We found that in both cultured astrocyte ([Fig. 5P and 5Q](#F5){ref-type="fig"}) and each Ttyh1/2/3-expressing HEK293T cells ([Fig. 5R](#F5){ref-type="fig"}), the reversal potential of I~Cl,swell~ shifted to a positive potential in gHOS treatment. Based on the reversal potential shift, we calculated the P~Glu~/P~Cl~ according to Goldman-Hodgkin-Katz equation and found that I~Cl,swell~ in cultured astrocytes and each Ttyh1/2/3-mediated I~Cl,swell~ shared the similar high P~Glu~/P~Cl~ at around 0.26 ([Fig. 5S](#F5){ref-type="fig"}). Taken together, these results indicate that kinase-dependency and glutamate-permeability of each TTYH-mediated I~Cl,swell~ resemble those of the astrocytic VRAC~swell~.

Arginine residue at 165 in TTYH1 and 164 in TTYH2 is the pore-forming amino acid as evidenced by mutagenesis-based structure-activity analysis
----------------------------------------------------------------------------------------------------------------------------------------------

If TTYH isoforms are the true channel-forming subunit of VRAC~swell~, we should be able to determine the channel-pore as a single amino acid residue. To identify the exact pore-forming amino acid residue, we first utilized bioinformatical approaches to predict the membrane topology of TTYH isoforms. Based on the dendrogram analysis ([Fig. 6A](#F6){ref-type="fig"}) and sequence alignment ([Fig. 7](#F7){ref-type="fig"}) of Ttyh1/2/3 isoforms across different species, we found that TTYH1, which is the most abundantly expressed isoform in astrocytes ([Fig. 1D](#F1){ref-type="fig"}), showed the order of sequence homology: TTYH1\>TTYH2\>TTYH3 \>\> *Drosophila* Tweety homologs. The hydrophobicity-based sequence analysis predicted a membrane topology with four highly-conserved trans-membrane domains (TM) and additional intra-membrane domain (IM) in TTYH1 or TM domain in TTYH2 and TTYH3 near the C-terminus ([Fig. 6B](#F6){ref-type="fig"}). To validate the predicted topology, we over-expressed the chimeric clone of TTYH1-GFP (GFP attached to the C-terminus of TTYH1) in HEK293T cells. We performed immunocytochemistry with either the antibody recognizing the N-terminus of TTYH1 (Ab~N-term~) or the GFP-antibody (Ab~GFP~) which should bind to the C-terminus of TTYH1-GFP ([Fig. 8A](#F8){ref-type="fig"}). The intracellular or extracellular topology of each terminus was determined by the presence of the membrane detergent Triton X-100, which allowed the access of antibodies to the cytosolic compartment. We found that both Ab~N-term~ and Ab~GFP~ showed positive immunoreactivity only when Triton X-100 was present ([Fig. 8A](#F8){ref-type="fig"}). These results indicate that contrary to the previous suggestion \[[@B53]\], TTYH1 has four TM domains and one IM domain with cytosolic N- and C-termini ([Fig. 8C](#F8){ref-type="fig"}). In support of this topology, we found that the location of Loop1 between TM1 and TM2 ([Fig. 8C](#F8){ref-type="fig"}) is in the extracellular region ([Fig. 8B](#F8){ref-type="fig"}).

Because channel-pores usually reside within a loop between two transmembrane domains, we next closely examined the loop-sequences of Loop1-4 of TTYH1 ([Fig. 8C](#F8){ref-type="fig"}) and found that Loop2 and Loop4 were highly conserved across different species but not Loop1 ([Fig. 7](#F7){ref-type="fig"}). Loop3 appeared to be too short for a pore. Therefore, we focused on Loop2 and Loop4 to search for the channel-pore. We generated a series of truncation mutants (Δ) with a 20 amino-acid-deletion for each loop2 and 4 and also recorded I~Cl,swell~. We identified potential candidates, Δ2A (S116-T135) and Δ2C (T156-A175) in Loop2 and Δ4B (L289-N304) in Loop4, which all showed an elimination of I~Cl,swell~ ([Fig. 8D](#F8){ref-type="fig"}). Then, we performed surface biotinylation assay for each candidate to eliminate the possibility that the disappearance of I~Cl,swell~ is due to an impaired surface expression of the channel protein. We eliminated Δ4B in Loop4 and ΔYY (ΔY299, Y300) in Loop4B as a potential pore because of the lack of surface expression of Δ4B and ΔYY ([Fig. 8E](#F8){ref-type="fig"}). We made additional truncation mutants with Δ2A and Δ2C into 5-amino-acid-deletions and narrowed down to Δ2A4, Δ2C2, and Δ2C3, which showed significantly reduced I~Cl,swell~ ([Fig. 8D](#F8){ref-type="fig"}). After examining the surface biotinylation results ([Fig. 8E](#F8){ref-type="fig"}), we found that the positively charged arginine residue at 165 position (R165) satisfied the definition of putative single amino acid pore residue, displaying a signficant reduction of I~Cl,swell~ ([Fig. 8F and 8G](#F8){ref-type="fig"}) and a positive shift in the reversal potential of about +7 mV ([Fig. 8G](#F8){ref-type="fig"}) without affecting the surface expression after substitution with alanine (R165A) ([Fig. 8E](#F8){ref-type="fig"}). This result suggests that the TTYH1-R165A is less permeable to Cl^−^ compared to TTYH1-WT. The substitution at the homologous residue, R164A in TTYH2 similarly showed significantly reduced I~Cl,swell~ ([Fig. 8H and 8I](#F8){ref-type="fig"}) indicating that the arginine residue (R165 for TTYH1 and R164 for TTYH2) is the key pore-forming residue. We further found that R165A mutant of shRNA-insensitive TTYH1, when co-expressed with all *Ttyh1/2/3* shRNA, failed to rescue the I~Cl,swell~ in astrocytes ([Fig. 8J and 8K](#F8){ref-type="fig"}), confirming that R165 is the putative pore residue. Taken together, R165 in TTYH1 and R164 in TTYH2 are the pore-forming amino acids located between TM2 and TM3.

Arginine residue at 165 in TTYH1 and 164 in TTYH2 is the pore-forming amino acid as evidenced by substituted cysteine accessibility methods (SCAM)
--------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether R165 and neighboring residues in TTYH1 are located at the pore lining vestibule, we performed the SCAM with cysteine substituted mutants of each of 10 amino acids from V161 to A170 ([Fig. 9A\~D](#F9){ref-type="fig"}). The control TTYH1-WT mediated I~Cl,swell~ was reduced by 9.01% with 100mM of MTSES which has no permeability through the plasma membrane, suggesting that there is a basal level sensitivity of TTYH1 for 100mM of MTSES ([Fig. 9A\~C](#F9){ref-type="fig"}). Among 10 amino acids, R165C was most significantly blocked by 100mM of MTSES with the highest block percentage (36.58%) ([Fig. 9A\~C](#F9){ref-type="fig"}), suggesting that R165 is the *bona fide* pore-forming amino acid residue, but not an amino acid involved in channel gating. The V164C was also substantially blocked by 100mM of MTSES (28.85%, [Fig. 9C](#F9){ref-type="fig"}). These results suggest that R165 might be located at the apex of the outer vestibule of the pore in TTYH1, whereas V164 might be partially buried in the outer vestibule ([Fig. 9D](#F9){ref-type="fig"}). Finally, to investigate whether one R165 functions as one pore in a multi-subunit complex or a collection of multiple R165 functions as an assembly of one pore, we recorded I~Cl,swell~ when the relative abundance of TTYH1-R165A and TTYH1-WT was varied in co-expression system ([Fig. 9E](#F9){ref-type="fig"}). Intriguingly, the I~Cl,swell~ was linearly reduced according to the relative abundance of TTYH1-R165A ([Fig. 9E](#F9){ref-type="fig"}), which fitted well with a straight line (R^2^=0942, p=0.006) but not with a dominance model of tetramer or pentamer \[[@B54]\]. These results suggest that, instead of an assembly of several R165\'s to form one functional pore, each R165 in a multi-subunit complex of TTYH1 homomeric channel constitutes an individual functional conducting pore as a part of a large conducting pore.

The I~Cl,swell~ is mediated by TTYH family in ex-vivo hippocampal astrocytes
----------------------------------------------------------------------------

Due to the lack of molecular identity, the brain distribution and *in-vivo* function of VRAC~swell~ have remained unknown. Using the antibody against TTYH1, which is the most abundant isoform, we found that the protein expression pattern of TTYH1 was exclusively in GFAP-expressing astrocytes in the hippocampus and cortex ([Fig. 10A](#F10){ref-type="fig"}). The astrocyte-specific expression and antibody specificity were verified by the use of adeno-associatedvirus carrying *Ttyh1*-specific shRNA ([Fig. 10B and 10C](#F10){ref-type="fig"}). Then, we recorded I~Cl,swell~ from *ex-vivo* astrocytes in acute hippocampal slices infected with either all *Ttyh1/2/3* shRNAs or control shRNA. After making a whole-cell patch configuration under the conventional artificial cerebrospinal fluid, we exchanged the external bath solution to the Tris-Cl based isotonic solution which contained 5mM TEA and 5mM BaCl~2~ to eliminate the K^+^ conductance of astrocytes and found that the reversal potential of the membrane current shifted from −80mV to near −10mV, which was the equilibrium potential for Cl^−^. Under these recording conditions, the HOS-induced astrocytic I~Cl,swell~ was significantly reduced by all *Ttyh1/2/3* shRNAs compared to control shRNA ([Fig. 10D\~F](#F10){ref-type="fig"}), indicating that I~Cl,swell~ of hippocampal astrocyte is mediated by Ttyh1/2/3. Taken together, these results indicate that TTYH family function as the astrocytic VRAC~swell~ *ex vivo*.

The astrocytic TTYH1/2/3 is necessary and sufficient for RVD in the hippocampus
-------------------------------------------------------------------------------

The primary role of VRAC~swell~ in volume regulation is its participation during RVD. To recapitulate RVD in hippocampal slices, we performed intrinsic optical signal (IOS) imaging which represents the astrocytic volume change through water movement via AQP4 upon repetitive neuronal activity \[[@B2][@B55]\]. Among various stimulation protocols, we found that low-frequency stimulation (LFS; 1 Hz) for 30 min at Schaffer-collateral pathway caused an RVD with a continuous increase in IOS, which peaked at around 15 min, followed by a steady decrease in IOS until the end of 30 min stimulation period ([Fig. 11A\~C, and 11E\~G](#F11){ref-type="fig"}). In contrast, a brief 20 Hz or 100 Hz stimulation only casued a transient IOS, but not DCPIBsensitive RVD ([Fig. 11D](#F11){ref-type="fig"}). The LFS-induced RVD was completely blocked by DCPIB and genistein treatments ([Fig. 11E\~G](#F11){ref-type="fig"}), raising a possibility that the LFS-induced RVD might be mediated by Ttyh1/2/3.

To test whether LFS-induced RVD is mediated by TTYH isoforms, we injected lentivirus carrying all *Ttyh1/2/3* shRNAs into CA1 hippocampus ([Fig. 11J](#F11){ref-type="fig"}) and found that the RVD was eliminated by all *Ttyh1/2/3* shRNAs ([Fig. 11J\~L](#F11){ref-type="fig"}). The eliminated RVD by all *Ttyh1/2/3* shRNAs was fully rescued by tamoxifen-dependent flanking of shRNAs, which are under the cre/loxP control (pSicoR system \[[@B44]\]) in hGFAP-CreERT2 mice ([Fig. 11H\~L](#F11){ref-type="fig"}). These results demonstrate that astrocytic Ttyh1/2/3 are necessary and sufficient for RVD in the hippocampus.

DISCUSSION
==========

Our study elucidates for the first time that TTYH family of genes encode the pore-forming subunits of VRAC~swell~ in the brain. Several lines of evidence support this conclusion: (1) The gene-silencing experiments using all three *Ttyh1/2/3* shRNAs reveal that expression of TTYH family is necessary for endogenous I~Cl,swell~ in astrocytes from both primary culture and hippocampal slice and for RVD in hippocampal slice; (2) Overexpression of each TTYH isoforms with AQP4 in HEK293T or CHO-K1 cells is sufficient for further increase of I~Cl,swell~ even in the absence of LRRC8A and this Ttyh1/2/3-mediated I~Cl,swell~ shares the same biophysical (outward-rectification, glutamate permeability), biochemical (Ca^2+^-independency, kinase-dependency) and pharmacological (sensitivity to DCPIB) properties as astrocytic VRAC; (3) The arginine residue at position 165 of TTYH1 and 164 of TTYH2 is the pore-forming amino acid of astrocytic VRAC as evidenced by a complete elimination of I~Cl,swell~ without any disturbance of surface expression by the pore-mutant of either TTYH1-R165A or TTYH2-R164A. This was further strengthened by the failure to rescue I~Cl,swell~ by overexpression of shRNA-insensitive TTYH1-R165A as opposed to the full rescue by overexpression of shRNA-insensitive TTYH1-WT when co-expressed with all three Ttyh1/2/3 shRNAs. The most striking evidence for R165 as the pore-forming amino acid residue comes from the significant block of TTYH1-R165C-mediated I~Cl,swell~ by MTSES in SCAM experiment. These lines of evidence provide unequivocal proof that TTYH family is the *bona fide* VRAC~swell~ of the brain.

TTYH family can function as a homomeric channel
-----------------------------------------------

One of the unique properties of an ion channel family is its ability to assemble as a homomeric or heteromeric complex to form a functional channel. For TTYH family there are three possible scenarios: (1) each TTYH subunits can assemble as a homomer; (2) TTYH subunits can assemble as a heteromer within TTYH family; and (3) TTYH subunits can assemble as a heteromer with other unknown proteins. Although we cannot completely rule out the possibilities of TTYH subunits assembling as heteromers, our results support the possibility that TTYH subunits can assemble and function as a homomer. If TTYH subunits were assembled only as a heteromer within TTYH family, gene-silencing by the combination of two shRNAs should have been effective to reduce the I~Cl,swell~ in astrocytes. However, this was not the case: Only the combination of all three shRNAs ([Fig. 2E, 2G and 2H](#F2){ref-type="fig"}), but not the combinations of two shRNAs ([Fig. 2E and 2F](#F2){ref-type="fig"}), was able to significantly and fully silence the I~Cl,swell~ in astrocytes. These strongly suggest that TTYH subunits can assemble and function at least as a homomer. It is also unlikely that TTYH subunits assemble with other unknown protein to form a functional channel because heterologous overexpression of each TTYH subunits produced an equal magnitude of I~Cl,swell~ in HEK293T and CHO-K1 cells, which are originated from human kidney and hamster ovary, respectively. The chance of such unknown protein to be expressed at high level in those two seemingly different cell lines and astrocytes is very low. More importantly, the strongest evidence for homomeric assembly of TTYH in astrocytes comes from the observation that co-expression of shRNA-insensitive TTYH1-WT with all three Ttyh1/2/3 shRNAs fully rescued I~Cl,swell~ ([Fig. 2E, 2G and 2H](#F2){ref-type="fig"}), whereas co-expression of the pore-mutant TTYH1-R165A (shRNA-insensitive) and all three Ttyh1/2/3 shRNAs caused a complete impairment of I~Cl,swell~ ([Fig. 8J and 8K](#F8){ref-type="fig"}). Therefore, we propose that astrocytic VRAC~swell~ is composed of mostly homomers of all three Ttyh1/2/3 subunits. Nevertheless, further studies are needed to clarify the exact subunit composition of the TTYH channel.

The relationship between TTYH family and LRRC8A
-----------------------------------------------

In this study, we provide unprecedented evidence that each Ttyh1/2/3 isoform acts as a pore-forming subunit of VRAC~swell~, while LRRC8A acts as a pore-forming subunit of VRAC~Γ~, which modulates the speed of cell swelling and subsequent activation kinetics of VRAC~swell~. These ideas are derived from the detailed analysis of activation kinetics of I~Cl,swell~ recorded from both *Lrrc8a* and *Ttyh1/2/3* shRNAs expressing cultured astrocytes ([Fig. 2I\~L](#F2){ref-type="fig"}). The observations that the peak amplitude of I~Cl,swell~ was almost completely eliminated by *Ttyh1/2/3* shRNAs without affecting the activation kinetics ([Fig. 2I and 2J](#F2){ref-type="fig"}), while there was no change in peak amplitude of I~Cl,swell~ with significantly slower activation kinetics by *Lrrc8a* shRNA ([Fig. 2K and 2L](#F2){ref-type="fig"}), implying that TYH1/2/3 and LRRC8A might directly or indirectly interact with each other and have distinct roles on activation of I~Cl,swell~ in astrocytes. In support of the possibility of a direct interaction, a recent report demonstrated that LRRC8A directly binds to other ion channels such as TMEM16A (ANO1) in response to swelling by coimmunoprecipitation assay \[[@B56]\], raising a possibility that LRRC8A might also interact with TTYH family.

In support of the possibility of an indirect interaction between TTYH-mediated VRAC~swell~ and LRRC8-mediated VRAC~Γ~, a recent report provided a crystal structure of the pore-forming subunits of LRRC8 family \[[@B29]\]. In this report, the authors clearly demonstrated that activation of LRRC8 requires reduced cytosolic ionic strength, but not swelling or membrane stretch \[[@B27][@B29]\]. Based on this report and our findings, we now propose a mechanistic model ([Fig. 12A](#F12){ref-type="fig"}) to give a more comprehensive view and to explain the observed difference in activation kinetics of I~Cl,swell~ after *Lrrc8a* shRNA and the maximal current density of I~Cl,swell~ by *Ttyh* shRNA in astrocytes. When HOS(Tris-Cl) is applied in cultured astrocytes, water permeates the astrocytic plasma-membrane through the abundant AQP4 water channel, down the gradient of osmotic pressure. At the intracellular vicinity of AQP4, the ionic strength is instantaneously lowered by the influx of water (due to a dilution of ionic concentration by water). This lowering of ionic strength at the local region activates and opens nearby LRRC8A-mediated VRAC~Γ~, allowing the Cl^−^ ions to initially influx through VRAC~Γ~. The influx of Cl^−^ ions is ensured and potentiated particularly during the current recording by the ramp protocol (a periodic voltage step to +100mV and ramping down to −100 mV). This influx of Cl^−^ ions through VRAC~Γ~ further accelerates the water influx via AQP4 and subsequently induces a cell-swelling. This cell swelling eventually activates and open TTYH-mediated VRAC~swell~. By this time the intracellular Cl^−^ concentration would have been significantly accumulated, and the opening of VRAC~swell~ allows efflux of Cl^−^ ions. And the water efflux through AQP4 follows the Cl^−^ efflux via VRAC~swell~, causing a regulatory volume decrease (RVD). Based on this mechanistic model, we propose that TTYH family constitute the pore-forming subunits of astrocytic VRAC~swell~ which senses the cell swelling, and LRRC8 family constitutes a modulatory channel, VRAC~Γ~ which senses the low cytosolic ionic strength to boost anionic influx, water influx, and cell-swelling, facilitating the activation of VRAC~swell~. This model now explains how the gene-silencing of LRRC8A by *Lrrc8a shRNA* slows the activation kinetics of I~Cl,swell~ without affecting the maximal current density of I~Cl,swell~. Taken together, the precise relationship between Ttyh1/2/3 and LRRC8A and the molecular mechanisms of activation and modulation of I~Cl,swell~ by the association of both TTYH-mediated VRAC~swell~ and LRRC8-mediated VRAC~Γ~ remain undetermined. Future investigations are needed to test those exciting possibilities.

Molecular mechanisms of volume sensing and VRAC activation
----------------------------------------------------------

The precise molecular mechanisms of sensing the cell swelling induced by hypo-osmotic shock, leading to an opening of VRAC~swell~ are poorly understood. Several hypothetical models for sensing the cell-swelling have been proposed \[[@B57][@B58][@B59]\]; (1) direct sensing of membrane stretch, (2) direct or indirect tethering to the cytoskeleton, (3) alterations in membrane curvature such as caveolae complex by mechanical or membrane-compositional changes, and (4) via interaction with integrins activated by the cell volume perturbation, and (5) via swelling-induced interaction between actin-binding protein (ACTN4) and a cytosolic member of ABC transporter superfamily (ABCF2) prevents ABCF2 from suppressing VRAC~swell~. Previous studies supporting these models have identified caveolin-1 and caveolin-related proteins that form a membrane curvature called caveolae in astrocytes \[[@B60]\]. This caveolin-1 is tethered to actin microfilaments \[[@B61]\] and positively modulates the activity of VRAC via c-Src tyrosine kinase \[[@B62]\]. Meanwhile, integrins are known to be associated with not only the extracellular matrix but also caveolin and positively regulate VRAC activation via various kinases such as FAK tyrosine kinase \[[@B63]\]. It has been previously demonstrated that a5-integrin is co-localized with TTYH1 in TTYH1-GFP over-expressing HEK293T cells \[[@B64]\]. We have demonstrated that Ttyh1/2/3-mediated I~Cl,swell~ is fully blocked by genistein and PD98059, which are the inhibitors of tyrosine kinase and MAP kinase, respectively ([Fig. 5A, 5D and Fig. 5H\~J](#F5){ref-type="fig"}). Based on these results, we can propose a mechanistic insight that there exists a complex of caveolin, integrin, cytoskeleton, and TTYH channels at astrocytic membrane curvature called caveolae, and hypo-osmotic shock somehow transduces through the integrin-caveolin-cytoskeleton complex to activate MAP kinase and tyrosine kinase to phosphorylate TTYH channels, which is required for either activation or surface expression of TTYH channels ([Fig. 12B](#F12){ref-type="fig"}). In support of this possibility, we have observed that the surface expression of TTYH1 is enhanced by HOS treatment and prevented by either TK or MAPK inhibitor ([Fig. 5K](#F5){ref-type="fig"}). These exciting possibilities await future investigations.

The physiological and pathological roles of TTYH family in the brain
--------------------------------------------------------------------

In addition to the fundamental role of VRAC~swell~ in cellular volume regulation, VRAC~swell~ is also implicated in many other functions including regulation of cell proliferation, apoptosis and motility, which occur during an early developmental stage in the embryonic neural stem cells \[[@B17][@B18]\]. Consistently, TTYH1 has been shown to be prominently expressed in embryonic stem cells during developmental stages and various brain structures in developing and adult brain, while limited expression was detected in non-neural tissues and cell types \[[@B65]\]. In the brain, TTYH1 appears to be associated with the general functions of VRAC~swell~ such as proliferation, apoptosis, and motility. For example, TTYH1 expression was shown to be increased at the edge of extending processes of the migrating cultured astrocytes after a scratch injury \[[@B66]\], suggesting its role in migration. TTYH1 expression is also increased in hypertrophied reactive astrocytes following *status epilepticus* \[[@B66]\], alluding to its role in morphogenesis. In glioma cells, TTYH1 was implicated as a potent regulator of tumor microtubule morphology, tumor-cell invasion, and proliferation \[[@B41]\], which are the putative functions of VRAC~swell~.

We have demonstrated that TTYH channels are highly permeable to glutamate (P~Glu~/P~Cl~ = 0.2\~0.3) ([Fig. 5O\~S](#F5){ref-type="fig"}), as VRAC~swell~ has been already shown to release glutamate and other osmolytes \[[@B8][@B9][@B10][@B15][@B51]\]. We have also demonstrated that 1 Hz stimulation in the Schaffer-collateral pathway in the hippocampus causes a profound volume increase and eventual TTYH1-mediated RVD ([Fig. 11J\~L](#F11){ref-type="fig"}). It is possible that glutamate released through TTYH channels during RVD might regulate synaptic transmission as well as synaptic plasticity. Consistent with this idea, it has been previously shown that taurine, released through DCPIB-sensitive VRAC~swell~, can mediate glycinergic neurotransmission in the hypothalamus \[[@B11]\]. We show that there is no contribution of DCPIB-sensitive RVD after a brief 20 Hz or 100 Hz stimulation at Schaffer-collateral pathway in the hippocampus ([Fig. 11D](#F11){ref-type="fig"}). In contrast, a prolonged 1 Hz stimulation, which is a conventional protocol for long-term depression (LTD) at this synapse, causes a profound increase in volume and initiation of RVD ([Fig. 11C, Fig. 11E\~G, J\~L](#F11){ref-type="fig"}). During such RVD, glutamate and other osmolytes are expected to be released through TTYH channels and affect synaptic transmission as well as NMDA receptor- or mGluR-dependent synaptic plasticity, in particular, LTD. These exciting possibilities should be explored in the future.

In conclusion, with the advent of molecular identification of TTYH family as the VRAC~swell~ of the brain, the putative functions of VRAC~swell~ can be systematically addressed at the molecular, cellular and systemic levels in the future. Furthermore, our study should provide novel therapeutic targets for cerebral edema following ischemic stroke, brain trauma, and brain cancer, which are known to be associated with VRAC~swell~ \[[@B14][@B67]\].
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![Neither *Lrrc8a* nor *Best1* encodes the pore-forming subunit of astrocytic VRAC~swell~. (A) Representative HOS-induced current (I~Cl,swell~) recordings from control shRNA and *Aqp4* shRNA-expressing cultured astrocytes. Inset (left): schematic diagram of whole-cell patch-clamp recording in primary cultured astrocyte. Inset (right): schematic diagram of ramp protocol from +100mV to −100mV. (B) Averaged I\~V curves for I~Cl,swell~ in control shRNA (black) and *Aqp4* shRNA (grey). (C) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV. Data are represented as mean±SEM (n=17 for control shRNA and n=15 for *Aqp4* shRNA; ^\*\*\*^p\<0.001, Mann-Whitney test). (D) Inverse correlation between the ΔCt value normalized by GAPDH measured by quantitative real-time quantitative PCR (qPCR) using cDNAs from hippocampal tissue (empty diamond), cultured cortical astrocytes (filled diamond) and FPKM value by RNA-sequencing that was previously shown in previous study (Zhang et al., 2014) to check relative mRNA expression of VRAC candidates such as *Ttyh* (*Ttyh1, Ttyh2* and *Ttyh3*), *Lrrc8* (*Lrrc8a, Lrrc8b, Lrrc8c, Lrrc8d* and *Lrrc8e*), and *Best* (*Best1, Best2* and *Best3*) family. Data are represented as mean±SEM of ΔCt normalized by GAPDH (n=3 for cultured astrocytes and n=2 for hippocampal slices; R^2^=0.428 for cultured astrocytes and R^2^=0.682 for hippocampal slices; nonlinear regression). (E, F) Upper panels, fluorescence images of mLRRC8A-GFP and control or *mLrrc8a* or *m/hLrrc8a* shRNA-mcherry co-expressing HEK293T cells. Bottom panels, western blot results confirming the efficiency for *mLrrc8a* shRNA or *m/h Lrrc8a* shRNA compare to control shRNA in mLRRC8A-overexpressed HEK293T cells. (G) Representative I~Cl,swell~ recordings from control shRNA, *Lrrc8a* shRNA, *Lrrc8c* shRNA and both *Lrrc8a* and *c* shRNAs-expressing cultured astrocytes. (H) Averaged I\~V curves for I~Cl,swell~ in control shRNA (black), *Lrrc8a* shRNA (orange), *Lrrc8c* shRNA (green) and both *Lrrc8a* and c shRNAs (sky blue). (I) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV. Data are represented as mean±SEM (n=11 for control shRNA, n=9 for *Lrrc8a* shRNA, n=8 for *Lrrc8c* shRNA, and n=9 for Lrrc8a/c shRNA; NS\>0.05, ordinary one-way ANOVA). (J--L) Representative traces, averaged I\~V curves and summary bar graphs of maximal I~Cl,swell~ currents from control or BEST1 KO mice in cultured astrocytes (n=14 for WT and n=10 for BEST1 KO; NS\>0.05, Mann-Whitney test). (M\~O) Representative traces, averaged I\~V curves and summary bar graphs of maximal I~Cl,swell~ currents from control (n=11) or BEST1 shRNA expressing condition (n=10) in cultured astrocytes (n=11 for control shRNA and n=10 for *Best1* shRNA; NS: p\>0.05, Two-tailed unpaired t-test).](en-28-183-g001){#F1}

![*Ttyh* family of genes encode the essential components of the astrocytic VRAC~swell~. (A) RT-PCR results confirming the efficiency of each *Ttyh1/2/3* shRNA in cultured astrocytes. Lentivirus containing each pSicoR *Ttyh1/2/3* shRNA were infected in cultured astrocytes. (B) Schematic diagram of the design of shRNA-insensitive clone of TTYH1. The upper sequence represents endogenous *Ttyh1* mRNA sequence that is complemented with *Ttyh1* shRNA. The lower sequence represents shRNA-insensitive clone of TTYH1 sequence that is not complemented with *Ttyh1* shRNA due to changing every third single nucleotide of *Ttyh1* shRNA target site to another nucleotide that makes same amino acid due to the codon redundancy. (C) RT-PCR results confirming the efficiency for shRNA-insensitivity using shRNA-insensitive clone of TTYH1 with control or *Ttyh1* shRNA compared to TTYH1-GFP with control or *Ttyh1* shRNA overexpressing HEK293T cells. (D) Fluorescence images of TTYH1-GFP and shRNA-insensitive clone of TTYH1 with control or *Ttyh1* shRNA expressing HEK-293T cells. (E) Representative I~Cl,swell~ from control shRNA, *Ttyh1/3* shRNAs, *Ttyh1/2/3* shRNAs, *Ttyh1/2/3* shRNAs with shRNA-insensitive clone of *TTYH1* (*Ttyh1* sh-insens.) expressing cultured astrocytes. (F) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV in the presence of single *Tty*h shRNA or any combination of double *Ttyh* shRNAs (*T1, T2, T3,* *T1/2*, *T1/3*, *T2/3* shRNAs). Data are represented as mean±SEM (n=10 for Naïve, n=14 for 7mg of control shRNA, n=10, 12 and 8 for 7mg of single *Ttyh1*, *Ttyh2*, and *Ttyh3* shRNA, n=8 for 14mg of control shRNA, n= 10, 10 and 10 for 14mg of double *Ttyh1/2*, *Ttyh1/3*, and *Ttyh2/3* shRNAs; NS\>0.05, Kruskal-Wallis test). (G) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV in naïve astrocytes and in the presence of control or *Ttyh1/2/3* shRNAs and *Ttyh1/2/3* shRNAs with shRNA-insensitive clone of TTYH1 expressing cultured astrocytes. Data are represented as mean±SEM (n=10 for Naïve, n=11 for control shRNA, n=13 for *Ttyh1/2/3* shRNAs, and n=18 for *Ttyh1/2/3* shRNAs with shRNA-insensitive clone of TTYH1; ^\*\*\*^\<0.001, NS\>0.05, Ordinary one-way ANOVA). (H) Averaged I\~V curves for I~Cl,swell~ in Control shRNA (grey), *Ttyh1/2/3* shRNAs (*T1/2/3* shRNAs, blue) and *T1/2/3* shRNAs with shRNA-insensitive clone of *TTYH1* (*Ttyh1* sh-insens; red). (I, K) Averaged current density values at ±100mV in every minute after HOS treatment in control (black), *Ttyh1/2/3* shRNAs (blue) and *Lrrc8a* (orange) expressing cultured astrocytes. Dot points are represented as mean±SEM. Lines (dark grey, sky blue, and orange) between each value were drawn by the fitting of sigmoidal 4^th^ order function. (n=11 for both control shRNA (grey), n=13 for *Ttyh1/2/3* shRNA (sky blue), and n=9 for *Lrrc8a* shRNA (orange)). (J, L) Normalized current density from +100 mV to −100 mV by maximum current amplitude in every minute after HOS treatment. Dot points are represented as mean±SEM. Lines (dark grey, sky blue, and orange) between each value were drawn by the fitting of sigmoidal 4^th^ order function. (n=11 for both control shRNA (grey), n=13 for *Ttyh1/2/3* shRNA (blue), and n=9 for *Lrrc8a* shRNA(orange)). Inset: The averaged time to 50% of peak. Data are represented as mean±SEM (n=11 for both control shRNAs, n=13 for *Ttyh1/2/3* shRNA, and n=9 for *Lrrc8a* shRNA).](en-28-183-g002){#F2}

![Each Ttyh1/2/3 isoform is sufficient for VRAC~swell~ activity. (A) Representative I~Cl,swell~ from Naïve, TTYH2 only, AQP4 only or TTYH1, TTYH2 and TTYH3 with AQP4 co-expressing HEK293T cells. Inset: schematic diagram of whole-cell patch-clamp recording in AQP4 (grey), TTYH1 (red), TTYH2 (blue), TTYH3 (green) expressing HEK293T cells. (B) Averaged I--V curves for I~Cl,swell~ in Naïve (black), TTYH2 only (skyblue), AQP4 only (grey), and TTYH1 (red), TTYH2 (blue), TTYH3 (green) with AQP4 co-expressing HEK293T cells. (C) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV. Data are represented as mean±SEM (n=18 for Naïve HEK293T cells, n=5 for TTYH2 over-expressing HEK293T cells, n=22 for AQP4 over-expressing HEK293T cells, n=21, 23 and 13 for TTYH1, TTYH2 and TTYH3 with AQP4 co-expressing HEK293T cells; ^\*^\<0.05, ^\*\*^\<0.01, ^\*\*\*\*^\<0.0001 and NS\>0.05, Kruskal-Wallis test). (D\~F) Representative traces, averaged I\~V curves and summary bar graphs of maximal I~Cl,swell~ currents from either TTYH1 or LRRC8A with AQP4 co-expressed CHO-K1 cells (n=15 for TTYH1+AQP4, n=10 for LRRC8A+AQP4; ^\*\*\*\*^p\<0.0001, Mann-Whitney test). (G) Representative traces of I~Cl,swell~ recording from naïve HEK293T cells during HOS (black bar) and NaCl^−^containing HOS (HOS(NaCl)) treatment, respectively (pink bar). (H) Averaged I\~V curves for maximal I~Cl,swell~ recorded from naïve HEK293T cells in response to HOS (black) and HOS(NaCl) (pink). (I) Summary bar graph showing the maximal amplitude for I~Cl,swell~ from +100 mV to −100 mV recorded from naïve HEK293T cells in response to HOS (black) and HOS(NaCl) (pink). Data are represented as mean±SEM (n=8 and 10 for HOS or HOS(NaCl); ^\*\*\*\*^\<0.0001, unpaired t-test). (J\~L) Representative traces, averaged I\~V curves, and summary bar graph of I~Cl,swell~ recorded from control shRNA (black), m/h *Lrrc8a* shRNA (orange)--expressing and TTYH1 (red), AQP4 (grey) with *m/h Lrrc8a* shRNA (orange)-expressing HEK293T cells in response to HOS(NaCl) (pink). Data are represented as mean±SEM (n=10, 11, and 11 for Control shRNA, m/h Lrrc8a shRNA, and TTYH1+AQP4 with m/h Lrrc8a; ^\*\*\*^\<0.001, one-way ANOVA). (M\~O) Representative traces, averaged I\~V curves and summary bar graphs of maximal I~Cl,swell~ currents from control shRNA or *m/h Lrrc8a* shRNA expressing condition in cultured astrocytes (n=9 for control shRNA, n=9 for *m/h Lrrc8a* shRNA; NS: p\>0.05, unpaired t-test). (P\~R) Representative traces, averaged I\~V curves and summary bar graphs of maximal I~Cl,swell~ currents from control shRNA expressing condition (n=10) or m/h Lrrc8a shRNA expressing condition (n=13) in HEK293T cells with expression of TTYH1+AQP4. Statistical analysis was performed with (NS: p\>0.05, Mann-Whitney test) Data are represented as mean±SEM for all averaged I\~V curves and summary bar graphs.](en-28-183-g003){#F3}

![Each Ttyh1/2/3 isoform shares the same biophysical (voltage-dependent inactivation, outward rectification), biochemical (Ca^2+^-independency) and pharmacological properties (sensitivity to DCPIB) as astrocytic VRAC~swell~. (A) Representative current traces with voltage step protocol from −100 mV to +140 mV, which is recorded in cultured astrocytes (black), TTYH1+AQP4 (blue), TTYH1+AQP4 with *m/h Lrrc8a* shRNA (green) expressing HEK293T cells, and naïve HEK293T cells (purple and red). The major constituent of HOS is indicated in each traces, (HOS(Tris-Cl) or HOS(NaCl). Bottom left, the schematic diagram of voltage step protocol and calculation of inactivation % (Inactivation % is calculated by a/b^\*^100, the 'a' indicates the initial 10% of current amplitude at +140 mV, and the 'b' indicates the last 90% of current amplitude at +140 mV). (B) Summary bar graph showing inactivation % at +140 mV. Data are represented as mean±SEM (n=8 for astrocytes by treating HOS(Tris-Cl), n=11 for TTYH1+AQP4 expressing HEK293T by treating HOS(Tris-Cl), n=9 for TTYH1+AQP4 with *m/h Lrrc8a* shRNA by treating HOS(NaCl), n=8 for naïve HEK293T cells by treating HOS(Tris-Cl), and n=14 for naïve HEK293T cells by treating HOS(NaCl), ^\*\*\*\*^\<0.0001, one-way ANOVA). (C) Summary bar graph showing rectification index from cultured astrocyte and naïve HEK293T by treating HOS(Tris-Cl) (black and blue) and from naïve HEK293T cells by treating HOS(NaCl) (red). (n=8 for astrocyte by treating HOS(Tris-Cl), n=11 for TTYH1+AQP4 expressing HEK293T cells by treating HOS(Tris-Cl), n=9 for naïve HEK293T cells by treating HOS(NaCl), ns\>0.05, one-way ANOVA). (D) Summary scatter plot showing the relative permeability of various anions such as SCN^−^, I^−^, Br^−^, and F- recorded from naïve HEK293T cells by treating Na^+^ containing HOS (grey circle) and recorded from TTYH1+AQP4 with *m/h Lrrc8a* shRNA expressing HEK3293T cells by treating Na^+^ containing HOS (skyblue square). (n=9, 8, 8, and 7 for naïve HEK293T cells for SCN^−^, I^−^, Br^−^, and F^−^, respectively, and n=8, 8, 8, and 8 for TTYH1+AQP4 with *m/h Lrrc8a* shRNA expressing HEK293T cells for SCN^−^, I^−^, Br^−^, and F^−^, respectively). (E) Summary bar graph showing rectification index (\|I~Cl,swell~ at −100 mV\|/I~Cl,swell~ at +100 mV) from whole-cell patch-clamp recording of cultured astrocyte and Ttyh1/2/3 with AQP4 co-expressing HEK293T cells. Data are represented as mean±SEM (n=24 for astrocytes and n=21, 23 and 13 for TTYH1, TTYH2 and TTYH3 with AQP4 co-expressing HEK293T cells; NS\>0.05, Kruskal-Wallis test). (F) Representative I~Cl,swell~ from TTYH1, 2 and 3 with AQP4 overexpressing CHO-K1 cells using 0.15 mM external Ca2+ and 20 mM BAPTA containing internal solution. Inset: schematic diagram of whole-cell patch-clamp recordings in TTYH1 (red), TTYH2 (blue) and TTYH3 (green) with AQP4 (grey) co-expressing CHO-K1 cells. (G) Averaged I\~V curves for I~Cl,swell~ recorded at TTYH1 (red), TTYH2 (blue) and TTYH3 (green) with AQP4 (grey) co-expressing CHO-K1 cells. (H) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from −100mV to 100mV. Data are represented as mean±SEM (n=10, 8 and 10 for TTYH1, TTYH2 and TTYH3 with AQP4 co-expressing CHO-K1 cells; NS\>0.05, Kruskal-Wallis test). (I, L) Representative traces of I~Cl,swell~ recording from cultured astrocytes and Ttyh1/2/3 with AQP4 co-expressing HEK293T cells during treatment HOS (black bar) and DCPIB (10 µM, sky blue bar). (J) Averaged I\~V curves for I~Cl,swell~ from cultured astrocytes in control (black) and DCPIB (sky blue). (K, M) Summary bar graph showing the maximal amplitude for I~Cl,swell~ from +100 mV to −100 mV in cultured astrocytes and Ttyh1/2/3 with AQP4 co-expressing HEK293T cells, respectively. Data are represented as mean±SEM (n=10 and 8 for control or DCPIB treatment in astrocytes; ^\*\*\*\*^\<0.0001, Mann-Whitney test; n=8, 15 and 8 for control or DCPIB treatment in each TTYH1, TTYH2 and TTYH3 with AQP4 co-expressing HEK293T cells; ^\*\*\*\*^\<0.0001, 2way ANOVA).](en-28-183-g004){#F4}

![Each Ttyh1/2/3 shares the same pharmacological properties (sensitive to both genistein and PD98059) as astrocytic VRAC~swell~. (A) Representative traces of I~Cl,swell~ recording from cultured astrocytes and Ttyh1/2/3 with AQP4 co-expressing HEK293T cells during treatment HOS (black bar) in the presence or absence of Genistein (50 µM, sky blue bar). Right upper insets represent cultured astrocytes and Ttyh1/2/3 (red, blue and green, respectively) with AQP4 (grey) over-expressing HEK293T cells. (B) Averaged I\~V curves for I~Cl,swell~ in control (grey) and genistein-treated group (sky blue) recorded from cultured astrocytes. (C, D) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV recorded from cultured astrocytes and Ttyh1/2/3 with AQP4 co-expressing HEK293T cells, respectively. Data are represented as mean±SEM (n=8 for both control and genistein treatment in astrocytes; ^\*\*^\<0.01, Wilcoxon test; n=10 for both control and genistein treatment in TTYH1 with AQP4 co-expressing HEK293T cells, n=12 and 9 for control and genistein treatment in TTYH2 with AQP4 co-expressing HEK293T cells, and n=10 and 15 for control and genistein treatment in TTYH2 with AQP4 co-expressing HEK293T cells; ^\*\*^\<0.01, ^\*\*\*^\<0.001, ^\*\*\*\*^\<0.0001, 2way ANOVA). (E) Representative traces of I~Cl,swell~ from cultured astrocytes during treatment hypo-osmotic solution (black bar) and then PD98059 (50 µM, pink bar). Inset: schematic diagram of whole-cell patch-clamp recording in primary cultured astrocyte. (F) Averaged I\~V curves for HOS induced current responses in control (black) and PD980959 (pink) recorded at cultured astrocytes. (G) Summary bar graph showing the maximal amplitude of HOS induced current density from −100mV to 100mV. Data are represented as mean±SEM (n=7 and 9 for control and PD98059; ^\*\*\*^p\<0.001; Mann-Whitney test). (H) Representative traces of I~Cl,swell~ from TTYH1 with AQP4 co-expressing CHO cells during treatment HOS and then PD98059 (50 µM). Inset: schematic diagram of whole-cell patch-clamp recording in TTYH1 (red) with AQP4 (grey) co-expressing CHO cells. (I) Averaged I\~V curves for HOS induced current responses in control (red) and PD98059 (pink) recorded at TTYH1 with AQP4-co-expressing CHO cells. (J) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from −100mV to 100mV. Data are represented as mean±SEM (n=7 and 9 for control and PD98059; ^\*\*^p\<0.01; Mann-Whitney test). (K) Surface expression of TTYH1 in response to HOS(Tris-Cl) in cultured astrocytes, which were prevented by either TK and MAPK inhibitor. (L, M) Representative traces and summary bar graph of I~Cl,swell~ recording from naïve HEK293T in the absence of drug (black bar) or in the presence of genistein (TK inhibitor, light purple) or PD98059 (MAPK inhibitor, green) induced by HOS(NaCl, Pink line). For G, n=10, 4, 7 for in the absence or presence of drug, genistein or PD98059 in HEK293T cells, ^\*\*^\<0.01, one-way ANOVA). (N) Summary bar graph showing block % of kinase inhibitor in cultured astrocytes (black, induced by HOS(Tris-Cl)), TTYH1+AQP4 overexpressed HEK293T cells (red, induced by HOS(Tris-Cl)), and naïve HEK293T cells (pink, induced by HOS(NaCl)). (n= 8, 10, and 4 for recorded from astrocyte, TTYH+AQP4 overexpressed, and naïve HEK293T cells after genistein treatment, and n= 9, 9, and 6 for recorded from astrocyte, TTYH+AQP4 overexpressed HEK293T cells, and naïve HEK293T cells after PD98059 treatment, ^\*\*^\<0.01, Two-way ANOVA). (O) Schematic diagram for experimental conditions to record glutamate permeability of I~Cl,swell~. HOS (black) is standard 83mM Cl^−^ containing the hypo-osmotic solution. gHOS (orange) is 70mM glutamate and 13mM Cl^−^ containing the hypo-osmotic solution. (P) Representative trace for glutamate permeability recording in cultured astrocytes. gHOS (orange) was treated at the peak of I~Cl,swell~ induced by standard HOS (black). (Q) Representative I\~V curves for I~Cl,swell~ were recorded under whole-cell patch-clamp in cultured astrocytes firstly in HOS (83 mM Cl^−^, black) and switched to gHOS (70 mM glutamate and 13 mM Cl^−^, orange) in the same cell. (R) Representative I\~V curve for I~Cl,swell~ in AQP4 (grey), TTYH1 (red), TTYH2 (blue), TTYH3 (green) with AQP4 co-expressing HEK293T cells, with standard HOS (black) changed to gHOS (orange) in the same cell. (S) Glutamate permeability ratio relative to Cl^−^ (P~Glu~/P~Cl~) of I~Cl,swell~ are summarized. P~Glu~/P~Cl~ was calculated from the Goldman-Hodgkin-Katz equation (see in methods). Data are represented as mean±SEM (n=6 for astrocytes and n=8, 10 and 8 for TTYH1, TTYH2 and TTYH3 with AQP4 co-expressing HEK293T cells; NS\>0.05, ^\*^\<0.05, Kruskal-Wallis test).](en-28-183-g005){#F5}

![Dendrogram with various species of TTYH family and the prediction of trans-membrane (TM) domains in TTYH1, 2 and 3 based on hydrophobicity with TMHMM software. (A) Phylogenetic tree indicates the genetic relationship of various species of TTYH family such as *mouse*, *rat*, *human*, *xenopus laevis* and *drosophila* TTYH family. The tree was constructed using maximum likelihood method with the bootstrap values at 1000 replicates by MEGA5. The evolutionary distances were computed using the Poisson correction method and are in the units of the number of amino acid substitutions per site. (B) Prediction results of hydrophobic trans-membrane (TM) domain (red) and hydrophilic-intracellular (purple) and extracellular (blue) part of TTYH1, 2 and 3.](en-28-183-g006){#F6}

![Multiple amino acids alignment of for various species of TTYH family. Multiple amino acids alignment for various species of TTYH family represents 4 strong hydrophobic and conserved trans-membrane (TM) domain (sky blue), 1 weak hydrophobic and conserved intra-transmembrane (IM) domain or TM (yellowish green) across the species and isoforms of TTYH. Loop1-4 are located between TM domains. The possible candidates of the pore regions which are decided by the recording of I~Cl,swell~ in [Fig. 8D](#F8){ref-type="fig"} are Δ2A4 (pink letter), 2C2 (yellowish green letter), 2C3 (green letter) and 4B (sky blue letter). The 165 arginine residue (R165, red letter) is in between Δ2C2 and 3. mTTYH1-B is indicated with dark-red box.](en-28-183-g007){#F7}

![R165 in TTYH1 is the pore-forming amino acid as evidenced by mutagenesis-based structure-activity analysis. (A, B) Non-permeabilized (−Triton X-100) and permeabilized (+Triton X-100) HEK293T cells expressing TTYH1-GFP were immunostained with N terminus of TTYH1 by anti-TTYH1 antibody, C terminus of TTYH1 by anti-GFP antibody and Loop1-FLAG-tagged-TTYH1 clone by anti-FLAG-tag antibody. (C) The prediction of membrane topology of TTYH1 based on permeabilization staining results and topology prediction software (TMHMM). Epitope for Ab~N-term~ antibody (red box), Δ2A4 (H131-T135, pink circle), Δ2C2 (V161-R165, yellow-green circle), Δ2C3 (M166-A170, green circle), Δ4B(L285-N304, sky blue), ΔYY (Y299-Y300, blue circle) and R165 (which was the pore of TTYH1) were also indicated. (D) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV recorded with WT or several truncation mutants of TTYH1 co-expressing HEK293T cells. Data are represented as mean±SEM (n=22 for AQP4 expressing HEK293T cells, n=57 for WT-TTYH1 with AQP4 co-expressing HEK293T cells, n=9 for loop1-TTYH1, n=7, 8, 11, 8 and 15 for related to loop2A-TTYH1, n=9 for loop2B-TTYH1, n=8, 6, 9, 10, 16, 11 for related to loop2C-TTYH1, n=7 for both loop2D and loop2E-TTYH1, n=8 for loop4A, n=8 and 15 for related to loop4B-TTYH1, and n=9, 11, 8, 9 and 8 for loop4C, D, E, F and G of TTYH1; ^\*\*^\<0.01, ^\*\*\*^\<0.001, ^\*\*\*\*^\<0.0001, Kruskal-Wallis test). (E) Surface expression of truncation mutants of TTYH1 that showed significant reduction of I~Cl,swell~ by biotinylation assay. (F, G) Representative traces and averaged I\~V curve for I~Cl,swell~ from wild-type (WT) and R165A-TTYH1 with AQP4 co-expressing HEK293T cells. (H) Representative traces for I~Cl,swell~ from TTYH2-R164A with AQP4 compared to TTYH2-WT with AQP4 overexpressing CHO cells. Inset: schematic diagram of whole-cell patch-clamp recording in R164A or WT-TTYH2 with AQP4 expressing CHO cells. (I) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from −100mV to 100mV. Date are represented as mean±SEM (n=4 and 9 for TTYH2-WT with AQP4 and TTYH2-R164A with AQP4 coexpressing HEK293T cells, ^\*\*^p\<0.01; Mann-Whitney test). (J) Representative I~Cl,swell~ recordings from *Ttyh 1/2/3* shRNAs with shRNA-insensitive clone of TTYH1-WT and *Ttyh1/2/3* shRNAs with shRNA-insensitive clone of TTYH1-R165A-expressing cultured astrocytes. Inset: schematic diagram of whole-cell patch-clamp recording in primary cultured astrocyte. (K) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV in the presence of the *Ttyh 1/2/3* shRNAs with shRNA-insensitive clone of TTYH1-WT (*Ttyh1* sh-insens.) or with shRNA-insensitive clone of TTYH1-R165A-expressing cultured astrocytes. Data are represented as mean±SEM (n=18 and 10 for *Ttyh1/2/3* shRNAs with shRNA-insensitive form of WT-TTYH1 and R165A-TTYH1 expressing astrocytes, respectively; ^\*\*\*\*^\<0.0001, unpaired t-test).](en-28-183-g008){#F8}

![R165 in TTYH1 is the pore-forming amino acid as evidenced by SCAM. (A) Representative traces of I~Cl,swell~ recording from TTYH1-WT and TTYH1-R165C with AQP4 co-expressing HEK293T cells during treatment HOS (black bar) in the presence or absence of MTSES (100 mM, blue bar). Left upper insets represent TTYH1-WT (red) and TTYH1-R165C (green) with AQP4 (grey) co-expressing HEK293T cells. (B) Averaged I\~V curves for I~Cl,swell~ recording from TTYH1-WT and TTYH1-R165C with AQP4 co-expressing HEK293T cells in the absence of MTSES (red and green, respectively) or presence of MTSES (100 mM, blue). (C) Summary bar graph showing the MTSES block percentage (%) recorded from TTYH1-V161C to TTYH1-A170C compared to TTYH1-WT with AQP4 co-expressing HEK293T cells. Data are represented as mean±SEM (n=11 for TTYH1-WT with AQP4 co-expressing HEK293T cells, n=8, 7, 10, 8, 14, 5, 9, 8, 8, and 10 for from TTYH1-V161C to TTYH1-A170C with AQP4 co-expressing HEK293T cells; ^\*\*\*^\<0.001, Ordinary one-way ANOVA). (D) Schematic diagram of pore-forming subunit of TTYH1 predicted by results from mutagenesis-based structure-activity analysis and SCAM experiment. (E) Summary graph showing the maximal current of I~Cl,swell~ (red, n=12, 10, 16, 9 and 11, respectively) according to the relative abundance of TTYH1-R165A, fitted with linear-regression (pink line, R^2^=0.942, p=0.006). The non-dominance model for tetramer and pentamer is indicated with dark-grey and grey lines (R^2^ between the experimental results and the dominance model of tetramer and pentamer were 0.582 and 0.520, respectively).](en-28-183-g009){#F9}

![The I~Cl,swell~ is mediated by TTYH family in *ex-vivo* hippocampal astrocytes. (A) Upper panels in the hippocampus show immunostaining for TTYH1 expression in GFAP-positive (arrow) and NeuN-positive cells (arrowhead) in the hippocampal CA1 region. The lower panel in the hippocampus shows higher magnification images of TTYH1 expression in GFAP-positive (left) and NeuN-positive (right) cells. Upper panels in the cortex show immunostaining for TTYH1 expression in GFAP-positive (arrow) and NeuN-positive (arrowhead) in the cortex. Lower panel in the cortex show higher magnification images of TTYH1 expression in GFAP-positive (right) and NeuN-positive (arrowhead) cells. (B) Immunostaining images from the hippocampus of C57BL/6J mouse injected with AAV-control shRNA (top) or AAV-*Ttyh1* shRNA (bottom) stained with DAPI (blue), TTYH1 (green), GFAP (red) and merged images by confocal microscope. Inset: High magnification images focusing on single GFAP-positive cells from the mouse injected with AAV-control shRNA or *Ttyh1* shRNA stained with DAPI (blue), TTYH1 (green), GFAP (red) and merged images. (C) Quantification of TTYH1 intensity in astrocytes (GFAP-positive cells) from hippocampal CA1 *stratum radiatum* (SR) injected with AAV-virus containing control or all *Ttyh1/2/3* shRNAs. Data are represented as mean±SEM (n=112 and 94 for control and *Ttyh1/2/3* shRNAs; ^\*\*\*\*^\<0.0001, unpaired t-test). (D) Top: schematic diagram of whole-cell patch-clamp recordings in SR (left) and representative images for bright-field and fluorescence images showing *Ttyh1/2/3* shRNAs--expressing astrocytes (right). Bottom: representative traces of I~Cl,swell~ in naïve, control and *Ttyh1/2/3* shRNAs expressing astrocytes in SR. (E) Averaged I\~V curves for I~Cl,swell~ in naive (black), control shRNA (blue) and *Ttyh1/2/3* shRNAs (red). (F) Summary bar graph showing the maximal amplitude of I~Cl,swell~ from +100 mV to −100 mV in the naïve, control and *Ttyh1/2/3* shRNAs. Data are represented as mean±SEM (n=10, 10 and 12 for naïve, control shRNA and Ttyh1/2/3 shRNA; ^\*\*^\<0.01, unpaired t-test).](en-28-183-g010){#F10}

![The astrocytic Ttyh1/2/3 is necessary and sufficient for RVD in the hippocampus. (A) Schematic diagram of intrinsic optical signal (IOS) imaging experiment in SR of the hippocampus. (B) Representative bright-field image for IOS recording in SR after stimulating the Schaffer-collateral pathway. A white arrowhead indicates an electrical stimulation electrode in the Schaffer-collateral pathway. A white dotted lined circle indicates regions of interest (ROI). (C) (Left) Schematic diagram for electrical stimulation protocol for inducing RVD in SR of the hippocampus. (Right) The representative trace of IOS change by prolonged 1Hz for 30 min electrical stimulation on the Schaffer-collateral pathway in CA1 hippocampus. The percentage of RVD is calculated with a portion of decreased transmittance (a) from the peak transmittance (b) during 1Hz, 30min stimulation. (D) Upper panels for the representative traces for IOS change indicated as astrocytic volume change before and after treatment of DCPIB (grey line) by brief 20Hz for 1 sec electrical stimulation on the Schaffer-collateral pathway in CA1 hippocampus. Lower representative trace for IOS change by 100Hz for 1 sec electrical stimulation on the Schaffer-collateral pathway in CA1 hippocampus. (E) Representative traces of IOS induced by low-frequency stimulation (LFS) for 30 min in control (black), with 10 mM DCPIB (green) and with 50 mM Genistein (pink). The 'a' indicates the difference between the peak of response and the value of end of stimulation. The 'b' indicates the value of the peak for calculating RVD % (as described in Fig. 11C, a/b^\*^100). (F) Averaged traces for normalized transmittance by the peak of each trace. (G, L) Averaged bar graph of RVD percentage (%). RVD% is calculated by a/b^\*^100. Data are represented as mean ± SEM (n=12, 7 and 7 for control and after DCPIB and Genistein treatment; ^\*^\<0.05, ^\*\*^\<0.01, Kruskal-Wallis test; n=10, 10 and 9 for control and *Ttyh1/2/3* shRNA injected C57BL/6J mice and pSicoR Ttyh1/2/3 shRNA injected in tamoxifen-treated hGFAP-creERT2 mouse, respectively; ^\*^\<0.05, ^\*\*^\<0.01, NS\>0.05, Kruskal-Wallis test) (H) Timeline from tamoxifen injection to IOS imaging. Tamoxifen was into hGFAP-CreERT2 by intraperitoneal (*i.p.*) injection for 6 days. On 7 day, lentivirus containing pSicoR *Ttyh1/2/3* shRNA were injected into CA1 stratum radiatum of the hippocampus. IOS imaging was done 2 weeks after virus injection. (I) In the presence of tamoxifen, the inactivated Cre (CreER) were converted to the activated form of Cre (CreERT), which were translocated into Nucleus. CreERT recognized loxP sites in pSicoR *Ttyh1/2/3* shRNA construct and cleaved the shRNA sequence. (J) Representative fluorescence images of lenti-viral carrying control or *Ttyh1/2/3* shRNA injected into SR of CA1 hippocampus (upper panel). Representative traces of 30 min LFS-induced IOS recording from control shRNA (black), *Ttyh1/2/3* shRNAs (red) injected C57BL/6J mice and glial rescue condition by pSicoR *Ttyh1/2/3* shRNAs injected in tamoxifen-treated hGFAP-creERT2 mouse (blue) (bottom panel). (K) Averaged traces for 30 min LFS-induced IOS recording.](en-28-183-g011){#F11}

![A mechanistic model of volume regulation. (A) A mechanistic model for the sequence of events after HOS treatment. LRRC8 (yellow), AQP4 (blue), TTYH (red) were indicated in astrocytes (circle). Water or Cl^−^ fluxes were indicated as a blue and green arrow, respectively. Bottom panel, the graphical diagram of cell swelling (grey) and channel activity (AQP4 indicated as blue, Lrrc8a indicated as yellow, and TTYH indicated as red) with the time after HOS treatment. (B) The schematic model for volume sensing and VRAC~swell~ activation upon inducing cell swelling by HOS. TTYH1, 2 and 3 might be located in the caveolae, which is the structure of the complex including caveolin-1 (green), Integrin (sky blue), and cytoskeleton (pink). After cell swelling, the inactive form of tyrosine kinase (purple) might be activated (orange, active TK).](en-28-183-g012){#F12}
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